Lifecell: Heute bei der Revolution von morgen dabei sein? - 500 Beiträge pro Seite

[Neoe]

Mit diesem Thread möchte ich ein Forum zum Werdegang von Lifecell eröffnen.
Meiner Meinung nach werden wir gerade Zeuge davon , wie sich Lifecell zur Nummer 1 mausert , obwohl sie eigentlich mit ihren starken Produkten noch gar nicht am Markt sind.
Nach dem letzten Deal mit LifeNet spielt es keine Rolle , wo die Qualität ihres Hauttransplantats einzuordnen ist:
..........................................................
ZU LIFENET:


Welcome to the LifeNet Website. LifeNet is the largest, full-service, non-profit allograft Tissue Banking System in the United States, providing human allograft tissue transplants to over 50,000 patients a year--worldwide. LifeNet is also a non-profit, federally-designated, Organ Procurement Organization (OPO) located in the United States, providing donation systems for heart, liver, kidney, pancreas, lung, and other organs for transplant. LifeNet was founded in 1982 to address the need for human organs and tissues for transplant.

LifeNet is an organization devoted to many different groups of people. The LifeNet website is frequented by our donor families, our recipients, surgeons and clinical staff, and many individuals who want to know more about LifeNet, organ and tissue donation and transplantation. In order to make site navigation as easy as possible, we have created the hot topics sections below to help you jump right to the subject in which you are interested.

If you have any questions, comments, suggestions or comments about the LifeNet website, please contact the LifeNet webmaster.


............................................................


ZUM DEAL MIT LIFENET:


LifeCell and LifeNet Partner to Increase Availability of Allograft Skin Tissue for Burn Victims
BRANCHBURG, N.J., Jan. 30 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC - news), a leader in developing and commercializing biologically based solutions to repair or replace the body`s damaged tissue, announced today that it has entered into an agreement with LifeNet, the largest organ procurement based tissue bank in the United States.

Under the terms of the agreement, LifeNet will supply donated allograft skin tissue to LifeCell for processing into cryopreserved skin and Alloderm® graftable tissue on a priority basis for treatment of burn victims. LifeNet will discontinue processing cryopreserved skin, however, it will continue to distribute cryopreserved skin processed by LifeCell. LifeCell is one of the largest processors of allograft tissue for burn victims in the United States. Additionally, LifeCell provides other tissue grafts for plastic reconstructive, urology and gynecology procedures.

``LifeNet is an accredited and well-respected organization and we are pleased that they have chosen LifeCell as a partner to process their allograft skin,`` said Paul Thomas, President and CEO of LifeCell. ``We share a common vision of maximizing the clinical benefit of donated human tissue and we look forward to a successful partnership.``

LifeCell`s tissue grafts are processed using the Company`s proprietary and patented tissue matrix technology platform and are used for the repair and replacement of damaged or inadequate tissue in numerous different clinical applications.

``We are extremely pleased to work together with LifeCell to ensure that allograft skin tissue is available on a priority basis for burn victims,`` said Bill Anderson, LifeNet`s President and Chief Executive Officer. ``LifeNet and its affiliated OPO partners are dedicated to ensuring that donated human tissue is available to help as many patients as possible. Our responsibility to donor families is to see that others benefit from the gift of donated human tissues and we are confident that this agreement will help us to meet that objective.``

LifeCell is a leader in developing and marketing biologically based solutions for the repair and replacement of damaged or inadequate tissue in numerous different clinical applications. The Company`s proprietary patented tissue matrix technology removes all cells from allograft tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently markets three human tissue based products: AlloDerm® for plastic reconstructive and burn procedures through LifeCell`s direct sales force and for periodontal procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in particulate form for the correction of soft tissue defects, through LifeCell`s direct sales force and a co-promotion agreement with OMP, Inc.; and Repliform(TM), a version of AlloDerm for urology and gynecology procedures, through a marketing and distribution agreement with Boston Scientific Corporation. The Company`s development programs include the application of its tissue matrix technology to vascular, nerve and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion.

LifeNet is the largest, full-service, non-profit allograft tissue bank in the United States. LifeNet provides quality tissue allografts to nearly 200,000 patients a year and related services to thousands of hospitals and clinicians -- worldwide. LifeNet was founded in 1982 to address the need for human organs and tissues for transplantation. LifeNet is also a non-profit, federally-designated, Organ Procurement Organization, providing donation services for heart, liver, kidney, pancreas, lung, and other organs for transplantation. LifeNet is an accredited member of the American Association of Tissue Banks, an institutional member of the United Network for Organ Sharing, an accredited member of the Association of Organ Procurement Organizations and is registered to the ISO 9001 quality management system. LifeNet is headquartered in Virginia Beach, Virginia, with regional offices across the country.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as our expectation for product development. Forward-looking statements represent management`s judgment regarding future events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements due to a number of factors. These factors include the risks detailed in the Company`s Annual Report on Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission.

SOURCE: LifeCell Corporation
........................................................................................................................



ÜBERAUS WICHTIGE PASSAGEN AUS OBENSTEHENDEN TEXTEN:


TEXT A: LifeNet....providing human allograft tissue transplants to over 50,000 patients a year--worldwide.

TEXT B:LifeNet will supply donated allograft skin tissue to LifeCell for processing into cryopreserved skin and Alloderm® graftable tissue on a priority basis for treatment of burn victims. LifeNet will discontinue processing cryopreserved skin, however, it will continue to distribute cryopreserved skin processed by LifeCell.


Aus A+B mach C:
Lifecell hat durch diesen Vertrag seine Distributionszahlen für die Zukunft auf erhebliche Weise gesteigert. Die Tragweite möchte ich hier nicht abschätzen , aber ich denke das spätestens im Q2-Ergebnis die Dimension klar wird.


Fazit: Alleine die geschaffenen Fakten (Profitabilität und angesprochener Vertrag) lassen Konkurrenten blass aussehen.Die Fantasie , die dieser Wert besitzt , kann man erahnen , wenn man sich nochmal die derzeitigen Forschungsgebiete , die oben auch beschrieben sind , zu Gemüte führt. Das Risiko des Scheiterns ist natürlich immer noch gegeben , aber im Vergleich zum Rest des Tissue-Company-Feldes ist das eher gering(nebenbei:Markt bis 2010:dreistelliger Milliardenbereich).

TIP(diesen hätte ich gerne von jedem , macht ja immer Spaß , sich damit etwas aufzuziehen , wenn es nicht so kommt):
bis Ende September mind. 7$
bis Ende Januar2003 mind. 10$

\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\


Kommentar von Kubrick aus meinem alten Thread(war leider schlecht aufzufinden):

Lifecell ist mit Sicherheit eine Firma mit enormen Potential. Das Wachstum mit ihren drei verfügbaren Produkten, hat sich allerdings merklich verlangsamt. Vor allem Cymetra scheint ein Ausfall zu sein. Die Orthopädischen Produkte (Bänder und Sehnen) und vor allem die hoffentlich 2002 verfügbaren Arterien könnten bei Erfolg, Lifecell in eine neue Umsatz Dimension katapultieren. Der Markt für gut funktionierende Arterien ist mit Sicherheit auf mehrere Milliarden Dollar zu schätzen. Wenn Lifecell es schafft in den ersten beiden Quartalen die Arterien auf den Markt zu bringen, lautet mein Tip für den Aktienkurs:

bis Ende September 02: >$14
bis Ende Januar 03: >$16

wenn nicht dann
bis Ende September 02: >$5
bis Ende Januar 03: >$6

@Neoe: du hast vergessen Lifecell als zu behandlende Aktie bei der Thread eröffnung anzugeben. Jetzt taucht der Thread nicht unter den Diskussionen über Lifecell auf. Vielleicht kannst du das ja ändern lassen

Gruß Kubrick

\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\

Also Kubrick , wie du siehst , habe ich das Problem nun behoben und hoffe auf etwas mehr Resonanz.
Mit dem Absatzproblem von Cymetra hast du wohl recht , aber es gab auch Leute die dem Hauttransplantat , derzeit die finanzielle Stütze von Lifecell , die Zukunft abgesprochen haben , was mit dem LifeNet-Deal wohl mehr als eindeutig widerlegt wurde.

[Neoe]

Zwei Dinge noch:

1.Anscheinend will Förtsch die Aktie in sein Depot aufnehmen , soll Mittwoch irgendwas im Aktionär stehen.Das gibt der Aktie meiner Meinung zwar nicht die entscheidende Daseinsberichtigung , aber da gäbe es glücklicherweise noch andere Meinungen.....

2.Lifecell stand in der Kritik Leichenhaut zu verwenden , anstatt wie z.B. Biotissue Eigenhauttransplantate zu ermöglichen.
Vor kurzem laß ich allerdings einen Spiegelartikel , in dem ausdrücklich zur Sprache kam , daß anfangs immer Leichenhaut transplantiert wird und danach , wenn die die neue Haut gezüchtet wurde , ein Austausch stattfindet.
Weiß einer mehr?

[Neoe]

Eins hab ich noch vergessen:
Lifecell ist seit dem letzten Quartal PROFITABEL!!!!
Das ist ein Novum in dieser Branche. Wenn man sich die Bewertungen der Konkurrenten(Organogenesis , AdvancedTissue)
anschaut ,die wohlgemerkt weit davon entfernt sind ,Gewinne zu erwirtschaften, wird es einem schwindlig vor Kurspotential.

[Neoe]

Am 26.Feb gibt es nun endlich die endgültigen Zahlen. Noch 7 Tage , der Countdown läuft. Das + ist muß , sonst geht es scharf nach unten. Habe persönlich aber keine Zweifel daran.

Ich erhoffe mir zudem eine Aussage über den Stand der weiteren Produkte und vielleicht mal eine Auskunft , was der Deal mit LifeNet eigentlich für Lifecell bedeutet.
Ich denke , daß die Vorteile , die daraus entstehen , enorm sind , aber das scheint noch nicht ganz in den Köpfen angekommen zu sein.
Nicht zu vergessen , daß LifeNet auch als Vertriebskanal für weitere Lifecell-Produkte genutzt werden könnte. Siehe Website-Text von LifeNet.

P.S.:Ich liebe Selbstgespräche

[Kubrick2001]

Hi Neoe,
Lifecell leidet zur Zeit unter Gewinnmitnahmen von Institutionellen.Der Tail Wind Funds, Ltd. hat am 11.02.02 478.001 Aktien zum Verkauf angeboten.

Ich bin mir ziemlich sicher das es nach Veröffentlichung des Jahresberichtes wieder aufwärts geht.

Lifecell wird im Abschlußbericht einen update über die Pipeline Produkte geben und vielleicht auch schon eine Zeitraum nennen, in dem sie ihre neu entwickelten Arterien auf den Markt bringen.
Zitat vom CEO von LIFC:"...we look forward to an exciting 2002 as we leverage LifeCell`s technology base to enter into larger target markets such as orthopedics and cardiovascular."


Schöne Grüße
Kubrick

[Neoe]

Danke , gut zu wissen ,daß da tatsächlich ein Update kommt.
Ich glaube wir sind uns darüber einig , daß "cardiovascular" in diesem Fall das Zauberwort für höhere Kurse ist.
Bis dann

[Kubrick2001]

@Neoe

Behalte auch ruhig mal eine Auge auf Biotissue. Sind zwar lange noch nicht so weit wie Lifecell aber die Produkte gefallen mir sehr gut. Wenn die Zahlen zum 4. Quartal (kommen ende März), die reduzierten Erwartungen erfüllen oder übertreffen werde ich weitere Aktien zu kaufen.

Gruß
Kubrick

[Neoe]

Biotissue beobachte ich schon länger, sind aber mit Sicherheit noch recht hoch bewertet. Ich kann nicht einschätzen inwiefern die Bewertung gerechtfertigt ist.

Wenn man Lifecells und Biotissues Hauttransplantate vergleicht , ist das von Biotissue wohl das bessere , aber Lifecell hat wie gesagt die Schäfchen mit dem LifeNet-Deal schon im Trockenen.

Was mir an Biotissue außerdem gefällt ist die Kooperation mit Baxter, was nun wirklich keine kleine Nummer ist.

Im Moment hab ich kein Geld auf der Hand , kann also so oder so nur zuschauen was passiert.

[Neoe]

Der wichtigste Teil der heutigen Meldung nochmal:

BRANCHBURG, N.J., Feb. 21 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC), a leader in developing and commercializing biological solutions to repair or replace the body`s damaged tissue, announced today that the Office of Naval Research has awarded the Company with an $824,000, three-year grant to continue funding of LifeCell`s cell preservation program.

Einerseits ist das sicher sehr positiv , andererseits weiß ich jetzt nicht genau , was ich mit dem Teil "three-year grant" anfangen soll.
Heißt das nun , daß Lifecell mit Thrombosol doch noch nicht soweit ist wie wir es schon vermutet oder gewollt hätten?

[Kubrick2001]

Hallo Neoe,

Thrombosol hat bis jetzt meines Wissens nach noch keine klinische Testphase durchlaufen.
Die M.D. Anderson Krebs Klinik führt zur Zeit im Auftrag von Lifecell die Studien durch.
Ich hoffe das wir mehr über den Stand von Thrombosol im conference call am Dienstag erfahren.

Das Lifecell jetzt weitere Forschungsgelder, erhält zeigt wie wichtig dieses Produkt ist.
Thrombosol ist meines Wissens nach das einzige Produkt, welches eine längere Lagerung von Blutkonserven, ohne Baktierielle Verunreinigungen ermöglicht (mehr als 5 Tage).
(Außerdem soll es bei der Behandlung von Leukämie helfen,weiß leider nicht in welcher Form)


P.S. Wie weit hast du denn gedacht ist Thrombosol?

Schöne Grüße
Kubrick

[Neoe]

Ich bin mir allgemein über den Entwicklungsstand der weiteren Produkte von Lifecell nicht ganz im Klaren. Die Website gibt da meiner Meinung nach recht wenig her. Aber ich hoffe , daß der nächste Dienstag mich erheblich schlauer machen wird.

Bis nächsten Dienstag erwarte ich auch , daß der Kurs nochmal anzieht.
Wenn im letzten Quartal tatsächlich Geld eingenommen wurde, der Ausblick positiv ist und ein weiteres Produkt absehbar ist, glaube ich , daß die 4$ nachhaltig überschritten werden.

Vielleicht weißt du ja auch , wie das mit der Zulassung in den USA läuft. Hier in Deutschland (ich beziehe mich hier auf die Biotissue-Auskünfte) braucht man ja anscheinend keine besondere Zulassung , um Tissue-Produkte zu vertreiben. Ist das in Übersee ähnlich oder schwingt in diesem Fall auch die FDA das Zepter?

[Neoe]

Es ist soweit , nächsten Dienstag werden die Hosen runtergelassen. Dann entscheidet sich , ob der Kurs wieder dahin zurückkehrt , wo er herkommt oder ob er sich aufmacht , um sich irgendwo jenseits der 4$ zu stabilisieren.

Für Spannung ist reichlich gesorgt. Wer sich gerne den CC live anhören möchte , kann sich hier schon mal anmelden.Kostet ja nichts:
http://www.videonewswire.com/event.asp?id=3615


Die Antwort auf mein vorheriges Posting kann ich mir mittlerweile selbst geben:

The FDA generally permits transplanted human tissue to be commercially distributed without obtaining prior FDA approval of the product. In contrast, products regulated as medical devices or biologics usually must undergo a lengthy, uncertain and expensive approval process. In 1996, the FDA determined that AlloDerm used for the repair or replacement of damaged or inadequate integumental tissue (i.e. "tissue lining the surface of the body or a body cavity") would be regulated as transplanted human tissue. On that basis, we continued commercial distribution of this product for plastic reconstructive, burn and periodontal surgery. In its decision with respect to the regulation of AlloDerm, the FDA stated that the regulatory status of any different uses, such as a void filler for soft tissue, for cosmetic augmentation procedures or as a wound healing agent, would need to be determined on a case-by-case basis.

Heißt also , daß zumindest die Chance besteht , daß die FDA auf übliche , zeitraubende Prozeduren auch bei künftigen Produkten verzichtet.

[t.1]

Lifecell hoch riskant - Analysen/Ausland
Nach Ansicht der Analysten des Anlegermagazins "Die Telebörse" ist die Aktie Lifecell Corp. (WKN 888910) ein hoch riskantes Investment.

Das Unternehmen habe bisher in erster Linie Hautersatz für Verbrennungswunden hergestellt. Man wolle die hier zu Grunde liegende Technologie nach und nach erweitern. Das erste Ziel sei die Herstellung von Blutgefäßen, die bei Bypassoperationen zum Einsatz kämen. Des weiteren forsche der Konzern daran, neues Knochengewebe zu züchten. Die schonende Lagerung von gespendeten Blutzellen sei ein drittes neues Feld.

Aufgrund der Terroranschläge in den USA habe Lifecell seine Umsatzprognosen auf 30,5 Mio. Euro für 2001 reduziert. Der Kurs sei auf Talfahrt gegangen. Das Unternehmen erwarte nun 25% Umsatzzuwachs auf 30,1 Mio. Euro in 2001. Zudem werde in Aussicht gestellt, im 4. Quartal erstmals Gewinne zu verzeichnen.

Die Aktie Lifecell ist gemäß den Analysten von "Die Telebörse" ein hoch riskantes Investment mit einer 100%-Chance.

[Neoe]

Die Tatsache , daß ich unter riskant was ganz anderes verstehe als die Telebörse , lässt die Analyse in meinen Ohren noch besser klingen. Ist aber schon einige Tage alt das Ding.



Hier mal noch was zur Aktionärsstruktur:
(ohne warrants)

Tail Wind Fund: 938,636
Special Situations Fund: 2,643,049
Vector Later Stage Fund: 1,640,653
Canadian Imperial Bank: 1,409,197
Ansonsten Involvierte: 1,910,000

Und hier noch andere Institutionelle:
Owner Name
MARXE AUSTIN W & GRE... 12/31/2001 2,643,050
ORBIMED ADVISERS INC... 12/31/2001 2,343,750
ORBIMED ADVISORS LLC 12/31/2001 2,343,750
WELLINGTON MANAGEMEN... 12/31/2001 368,200
DFA INVESTMENT DIMEN... 12/31/2001 317,000
VANGUARD GROUP INC 12/31/2001 162,200
KANALY TRUST CO 12/31/2001 125,869
KILKENNY CAPITAL MAN... 12/31/2001 63,500
BRIDGEWAY CAPITAL MA... 9/30/2001 22,900
NORTHERN TRUST CORP 12/31/2001 21,773
PENN MUTUAL LIFE INS... 12/31/2001 19,000
FIDUCIARY TRUST CO 12/31/2001 14,000
BEAR STEARNS & CO IN... 12/31/2001 13,000
CITIGROUP INC 12/31/2001 10,792
DEUTSCHE BANK AG 12/31/2001 6,900
BABSON DAVID L & CO ... 12/31/2001 900
BARCLAYS GLOBAL INVE... 12/31/2001 600
MERRILL LYNCH & CO I... 12/31/2001 197


Das heißt es sind momentan rund 75% oder ca. 17 Mio von 23 Mio. Aktien in mehr oder weniger fester Hand.

[t.1]

29.01.02 Aktienservice Research
LifeCell spek. Verdopplungschance - Analysen/Ausland
Die Analysten von Aktienservice Research empfehlen derzeit dem Anleger die Aktien von LifeCell (WKN 888910) zum Kauf.

LifeCell sei ein Biotech-Unternehmen, das biologische Lösungen für Ersatz und Wiederherstellung von geschädigtem Gewebe (Tissue-Engineering) anbiete. Im Hinblick auf Terroranschläge habe LifeCell seine Umsatzprognosen reduziert. Der Kurs habe zu diesem Zeitpunkt deutlich nachgegeben. Zum Jahresbeginn habe sich jedoch der NewsFlow bei LifeCell verbessert, so erwarte man nun 25 Prozent Umsatzzuwachs auf 26,6 Millionen Euro in 2001. Zudem werde in Aussicht gestellt, im vierten Quartal erstmals operative Gewinne zu erzielen. Dies habe dem Kurs wieder deutlich Auftrieb verliehen.

Mit einer Marktkapitalisierung von 65 Millionen US-Dollar (02e-Umsatzmultiple liege lediglich ca. zwei) sei der Titel für ein prosperierendes Biotech-Unternehmen sehr günstig bewertet. Befürchtungen, wonach dem Unternehmen in ca. 24 Monaten auf Grund der anhaltenden Verlustsituation die Mittel ausgehen könnten, seien durch den jüngsten Vorstoß in die operative Gewinnzone abgeschwächt bzw. widerlegt worden.

Auch die fundamentalen Aussichten würden sich bei LifeCell recht positiv gestalten. LifeCell habe bisher vornehmlich Hautersatz für Verbrennungswunden hergestellt und habe hier bereits drei Produkte auf den Markt bringen können. Die hierbei entwickelte Technologie und die erworbene Kompetenz solle nun auf weitere Indikationsgebiete erweitert werden, so zum Beispiel auf die Herstellung von Blutgefäßen, die bei Beipassoperationen zum Einsatz kämen, und auf die Züchtung von neuem Knochengewebe.

LifeCell verfolge mehrere hochinteressante Entwicklungsprojekte, so bspw. die Züchtung durch biotechnologische Prozesse von Arterien für Patienten, die an Arteriosklerose erkrankt seien. Da dies und damit verbundene Krankheitsbilder in den Industriestaaten immer noch Todesursache Nummer eins seien, adressiere LifeCell hiermit einen immensen Markt. Weitere Forschungserfolge würden vor diesem Hintergrund mit der Konkretisierung eines extremen finanziellen Potenzials einher gehen.

Ferner komme dem Unternehmen im Kerngeschäftsbereich Tissue-Engineering die wachsende Nachfrage nach kosmetischen Operationen zu Gute. Dieses Geschäftsfeld erscheine langfristig attraktiv, selbst bei Nicht-Berücksichtigung der laufenden Entwicklungsprojekte auf anderen Gebieten sei die Aktie nach Einschätzung von Aktienservice Research derzeit attraktiv bewertet.

Im prosperierenden Bereich Tissue-Engineering sei die marktführende LifeCell erste Wahl, erziele bereits nachhaltige Umsätze mit drei auf Basis von biotechnologischen Prozessen eigenentwickelten Produkten (AlloDerm, Cymetra und Repliform), die erfolgreich auf den Markt gebracht worden seien. Das sei erheblich mehr, als andere im Bereich Bio-Tissue angesiedelte Unternehmen vorweisen könnten. Vielversprechend positioniert sehe Aktienservice Research LifeCell hierbei im Heimatmarkt USA, da die Nachfrage nach Hautprodukten gerade auf Grund der boomenden Schönheitschirurgie gerade in den USA schnell ansteige.

Nach Einschätzung von Aktienservice Research sichere die aussichtsreiche Entwicklung des Kerngeschäfts alleine das heutige Kursniveau ab. Sollten erste Forschungserfolge bei der Züchtung von Arterien verzeichnet werden können, werde der Aktienkurs von LifeCell voraussichtlich explodieren. Vor diesem Hintergrund sehe Aktienservice Research bei LifeCell ein langfristig positives Chance/Risiko-Profil. Mit Sicht auf zwölf Monate werde das Kursziel bei sieben US-Dollar gesehen.

Das Rating der Analysten von Aktienservice Research für die LifeCell-Aktie lautet auf spekulativ kaufen. Auf Grund der jüngsten Kursbewegungen könnte zunächst eine Konsolidierung eintreten. Der Stoppkurs sollte bei 2,90 US-Dollar platziert werden.

@neoe bin selber drin wie du in den alten berichten nachlesen kannst,mir ging es wie in diesem bericht um die 100% die da drin sind.
grüße t.1

[Neoe]

t.1@:
Hab ich schon verstanden ; ich wollte nur sagen, daß ich die Sache als nicht so risikoreich ansehe , wie die Telebörse und die sowieso schon eher positiv angehauchte Analyse deswegen noch positiver bewerte.

Bis bald , wir gehören ja eher noch zur Minderheit. Die Tissue-Aktien sind hier scheinbar noch nicht allzu beliebt.
Dabei sind die Dinger eigentlich besser als typische Biotech-Aktien. Allein schon weil eine FDA-Zulassung nicht zwangsläufig nötig ist.
Das mindert das Verlustrisiko enorm , zudem ist der Markt für Tissue-Produkte auch nicht viel kleiner als der restliche Biotech-Markt und ist dabei noch nicht so überbevölkert.

[Pieselwitz]

Was heißt denn hier "Minderheit" meine Herren, ich bin schließlich auch schon seit längerem in Lifecell investiert!!

Denke derzeit auch über ein Investment in Biotissue nach. Wann kommen denn deren Zahlen??

MfG Pieselwitz!!

[Kubrick2001]

@Pieselwitz

26.03.02

Kubrick

[t.1]

LifeCell Corporation Invites You to Join Its FOURTH Quarter 2001 AND FULL YEAR Results Conference Call
2/20/02




BRANCHBURG, N.J., Feb 20, 2002 /PRNewswire-FirstCall via COMTEX/ -- In conjunction with LifeCell Corporation`s Fourth Quarter 2001 and Full Year Earnings Release, Paul G. Thomas, Chairman, President and CEO of LifeCell Corporation will be hosting a conference call on Tuesday, February 26, 2002 at 10:00 AM EST. A listen-only, live webcast of the conference call will be available at the following link: http://www.videonewswire.com/event.asp?id=3615. (Minimum requirements to listen to the webcast: The RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, and at least a 14.4Kbps connection to the Internet.)


What: Fourth Quarter 2001 and Full Year Earnings Release

When: Tuesday, February 26, 2002
10:00 AM EST

Conference Call Information

Participants: 800-711-5301

Access Code: LifeCell

Replay #: 888 566-0175

-- Available approximately 2 hours after event ends.
From February 26, 2002 through March 5, 2002

Contact: Steven Sobieski, VP, CFO, 908-947-1100

@kubrick wenn ich das richtig lese ist aber der 26.02.2002 gedacht nicht der 26.03.2002
grüße t.1

[Pieselwitz]

Dankeschön!

Werde mal die nächsten Tage noch in mich gehen!

MfG Pieselwitz!

[Neoe]

Jahresabschlußbericht 2001 Lifecell


LifeCell Reports Fourth Quarter and Full Year 2001 Financial Results

Reports Record Product Revenues for 2001 and Fourth Quarter Net Income

BRANCHBURG, N.J., Feb. 26 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC), a leader in the development and commercialization of biological solutions to repair or replace the body`s damaged tissue, today reported financial results for the fourth quarter and year ended December 31, 2001.

Highlights
* 2001 product revenues of $26.6 million, a 25 percent increase over 2000
* First time net income in the fourth quarter of 2001
* A decrease in net loss to $2.1 million in 2001 from $7.1 million in
2000

Fourth Quarter 2001

The Company reported product revenue of $6.7 million for the fourth quarter of 2001, up 19 percent from $5.6 million for the same period in 2000. The increase in product revenues in the fourth quarter of 2001 was largely due to increased demand for the Company`s AlloDerm(R) and Repliform(TM) products.

Net income for the fourth quarter rose to $102,000 compared to a net loss of $2.2 million in the fourth quarter of 2000. The improvement in net income was principally due to an increase in net contribution resulting from the increase in product revenue, improved efficiency in our tissue processing and reduced general and administrative expenses. At the same time, LifeCell was able to maintain its previous level of investment in research & development activities to fuel future growth of new products.

"Reaching profitability is an important milestone for LifeCell," said Paul Thomas, President and CEO of LifeCell. "We have turned our operating performance around, succeeded in our existing markets and are poised for substantial growth as we target the larger orthopedic and cardiovascular markets." Full Year 2001 Results

Product revenues for the year increased 25 percent to $26.6 million from $21.3 million in 2000. The increase in product revenues in 2001 was largely due to increased demand for the Company`s AlloDerm(R) and Repliform(TM) products.

Net loss for the year decreased to $2.1 million compared to a net loss of $7.1 million in 2000. The decrease in net loss was principally due to an increase in net contribution resulting from the increase in product revenue and a reduction in general and administrative expenses. Conference Call

As previously reported, a conference call will be conducted by LifeCell management today, February 26, 2002 at 10:00 a.m. Eastern time to discuss these operating results and related matters. You may listen to the conference call by calling [phone] and indicating access code: LifeCell. The conference call will be recorded and an automated playback of the conference call will be available through March 5, 2002 by dialing [phone] and indicating access code LifeCell.

A listen-only, live webcast of the conference call will be available at http://www.videonewswire.com/event.asp?id=3615. If you are unable to listen during the live webcast, the call will be archived on LifeCell`s web site http://www.LifeCell.com/about/ through March 5, 2002. About LifeCell

LifeCell is a leader in developing and marketing biologically based solutions for the repair and replacement of damaged or inadequate tissue in numerous different clinical applications. The Company`s proprietary patented tissue matrix technology removes all cells from allograft tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently markets three human tissue based products: AlloDerm(R) for plastic reconstructive and burn procedures through LifeCell`s direct sales force and for periodontal procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in particulate form for the correction of soft tissue defects, through LifeCell`s direct sales force and a co-promotion agreement with OMP, Inc.; and Repliform(TM), a version of AlloDerm for urology and gynecology procedures, through a marketing and distribution agreement with Boston Scientific Corporation. The Company`s development programs include the application of its tissue matrix technology to vascular, nerve and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as our expectations for growth, product development and entry into target markets. Forward-looking statements represent management`s judgment regarding future events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements due to a number of factors. These factors include the risks detailed in the Company`s Annual Report on Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission.

LIFECELL CORPORATION
Financial Highlights
(Unaudited)

Statement of
Operations Data: Three Months Ended Year Ended
December 31, December 31,
2001 2000 2001 2000
Revenues:
Product revenues $6,671,000 $5,586,000 $26,560,000 $21,330,000
Research grant
revenues 222,000 273,000 1,209,000 1,442,000

Total revenues 6,893,000 5,859,000 27,769,000 22,772,000


Costs and Expenses:
Cost of products
sold 2,060,000 2,156,000 8,862,000 6,949,000
Research and
development 1,064,000 1,104,000 4,351,000 4,523,000
General and
administrative 821,000 1,664,000 4,098,000 6,180,000
Selling and
marketing 2,793,000 3,077,000 11,978,000 11,779,000
Total costs and
expenses 6,738,000 8,001,000 29,289,000 29,431,000

Income (Loss) from
Operations 155,000 (2,142,000) (1,520,000) (6,659,000)

Interest and other
expense, net (53,000) (42,000) (550,000) (479,000)

Net Income (Loss) 102,000 (2,184,000) (2,070,000) (7,138,000)

Preferred Stock
and Deemed
Dividends (a) (1,151,000) (187,000) (1,591,000) (636,000)

Net Loss Applicable
to Common
Stockholders $(1,049,000) $(2,371,000) $(3,661,000) $(7,774,000)

Loss per Common Share -
Basic and Diluted $(0.05) $(0.15) $ (0.20) $(0.54)

Shares Used in Computing
Loss per Common Share -
Basic and
Diluted 19,964,000 16,001,000 18,240,000 14,372,000

December 31, December 31,
Balance Sheet Data: 2001 2000
Cash and cash equivalents
and short-term investments $4,900,000 $5,535,000
Working capital 8,851,000 5,330,000
Total assets 23,131,000 25,410,000
Common Stock, subject to redemption (b) 1,935,000 3,885,000
Total stockholders` equity (b) 14,833,000 8,904,000

(a) The Company recorded a deemed dividend resulting from the issuance of
additional shares of common stock in November 2001 to one of its
investors pursuant to the terms of an investment made in 1999.

(b) The 2000 stockholders` equity balance was revised to reclassify
certain shares from stockholders` equity to common stock, subject to
redemption.

////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

Den Damen und Herren kann man zu ihrer Seriösität wirklich nur gratulieren.
Versprochene Profitabilität in Q4 erreicht und was ich besonders löblich finde: Sie haben es nicht nötig ihre Forschungsgelder mit den Einnahmen zu verrechnen.
Wenn ich mich so umschaue , ist das glaube ich eher eine Ausnahme.

[Neoe]

Naja , CC ist nicht allzu aufregend:

Nächstes Jahr ca. 20% Wachstum , rund 32 Mio $ Einnahmen.
Und ich glaub irgendwas mit rund 1 Mio $ Gewinn(falls die cardiovascular grafts bald auf den Markt kommen, wohl viel zu konservativ).

Cardiovascular grafts sollen noch 2002 auf den Markt. Tierversuche hat man bereits (einige) hinter sich. Wenn ich es richtig verstanden habe , sollen sie aber anfangs nur im Beinbereich genutzt werden. So oder so soll dann ein gewaltiger Umsatzzuwachs ins Haus stehen.

Thrombosol ist anscheinend noch in einem sehr frühen Stadium , die Technik soll aber in mehreren Bereichen zum Einsatz kommen.

Mit LifeNet arbeitet man jetzt anscheinend auch im Forschungsbereich in einigen Dingen zusammen.

Ergebnis:
Die Sache hört sich noch immer so positiv wie gestern , vorige Woche oder vorigen Monat an. War vielleicht jetzt auch zuviel verlangt , heute gleich nochmal eine Riesenüberraschung zu erwarten.

[Neoe]

Börsenlogik pur. Alle Erwartungen erfüllt , Kurs im roten Bereich.

Dabei wurde es doch indirekt angekündigt , daß 2002 erheblich besser verlaufen könnte als angekündigt. Man wollte den Mund halt nicht zu voll nehmen , was gut ist , aber Börsianern leider nicht gefällt.

[Neoe]

Wenigstens die 3$ scheinen zu halten , hat sich ja vor geraumer Zeit schon mal als schöner Widerstand erwiesen.

Ansonsten ziehe ich mich in mein Schneckenhaus zurück und warte bis alle Debilen raus sind.

[Neoe]

Static Reanimation of the Paralyzed Face
With an Acellular Dermal Allograft Sling
Catherine P. Winslow, MD; Tom D. Wang, MD; Mark K. Wax, MD
Facial paralysis results in profound functional and cosmetic disabililities. Early rehabilitation
with nerve grafts is an excellent means of reanimating the face but is not always
possible. Dynamic rehabilitation may be precluded by surgical disruption of the vascular
supply or the intrinsic musculature. In these instances, static rehabilitation affords
an alternative means of addressing the lower part of the face. Any synthetic foreign implant
presents a potential for infection and extrusion. We describe a case of a static sling performed with
acellular dermis (AlloDerm; LifeCell Corp, The Woodlands, Tex).
REPORT OF A CASE
A 79-year-old male physician presented
with a recurrent neurotropic squamous
cell carcinoma of the parotid gland.
The skin carcinoma had become apparent
2 years earlier. The patient had
undergone 2 previous excisions. He was
referred after an ipsilateral progressive
facial palsy was noted. A magnetic resonance
imaging scan revealed enhancement
of the nerve to the stylomastoid
foramen. A fine-needle aspirate revealed
recurrent carcinoma. The patient agreed
toundergotumorextirpationwithfacialrehabilitation.
Anticipated ocular rehabilitation
consisted of a gold weight placement,
canthoplasty, and a browlift. The
possibility of facial nerve grafting and
dynamic or static oral reanimation was
also discussed. Postoperative radiation
therapy was planned.
Intraoperatively, the tumor involved
the facial nerve from the stylomastoid foramen
to small distal branches. The superficial
temporal artery and the masseter
muscle were resected for oncologic reasons,
precluding dynamic rehabilitation.
Therefore, primary static rehabilitation,
consisting of ipsilateral placement of a gold
weight, browpexy, and lateral canthoplasty
for the ocular effects of his facial paralysis,
was performed. Acellular dermis was
used to sling the oral commissure.
The patient underwent an uncomplicated
6-week course of radiation therapy.
He has been followed up for 6 months to
date and has done well. He experienced
some mucositis with therapy, but has had
no extrusion or problems related to the acellular
dermal sling. He has had no drooling
or difficulty with chewing, and his speech
is completely intelligible.
PROCEDURE
The surgical approach was facilitated by
the tumor extirpation. The preauricular incision
provided access to the zygoma. A
3-0 polypropylene suture was placed circumzygomatically
to anchor the graft laterally.
Medial tunneling in the subcutaneous
plane facilitated proper placement.
Incisions in the vermilion border of the upper
and lower lips were used to ensure
proper attachments to this region. A dermal
absorbable suture was used to anchor
the graft to the melolabial fold. The
acellular dermal graft was split to individually
address the upper and lower lips.
It was anchored medially and fed through
the tunnel (Figure 1). The circumzygomatic
suture was then tightened to the
point of minimal elevation of the corner
of the mouth (Figure 2). Drains were
placed and incisions were closed. The pa-
From the Department of Otolaryngology–Head and Neck Surgery, Oregon Health
Sciences University, Portland. Dr Winslow is now with the Department of Surgery,
Section of Otolaryngology–Facial Plastic Surgery, Walter Reed Army Medical Center,
Washington, DC.
FELLOW’S PAGE
(REPRINTED) ARCH FACIAL PLAST SURG/VOL 3, JAN-MAR 2001 WWW.ARCHFACIAL.COM
55
©2001 American Medical Association. All rights reserved.
tient did well postoperatively, with no complications. He
demonstrated an appropriate amount of commissure elevation
after surgery, which has not altered in 6 months
(Figure 3).
COMMENT
Resection of the facial nerve leads to significant functional
and cosmetic disabilities. The cosmetic changes are
evident immediately. The asymmetry in the face worsens
with time, as dynamic rhytids abate unilaterally. Functional
issues include drooling, nasal valve collapse, visual
obstruction, and corneal irritation. Inability to
completely close the eye can lead to corneal scarring and
eventual blindness.
Reanimation with nerve grafts, cranial nerve XII to
VII crossover, and microvascular nerve and muscle transfer
techniques have all been described. Dynamic rehabilitation
is possible with muscle transfer, such as that
of temporalis or masseter muscle. However, patients who
undergo resection of large facial or parotid carcinomas
may not be candidates for such procedures. Compromise
of the innervation or vasculature, in addition to
muscle resection, makes dynamic rehabilitation an unsuitable
option.
Patients undergoing resection of the facial nerve for
either recurrent or primary carcinoma are candidates for
simultaneous reanimation. Protection of the eye, which
is critical, can be provided by gold weight placement for
the upper eyelid and canthoplasty, if necessary, for the
lower eyelid. Alternatives include dynamic rehabilitation
or spring placement. Browpexy can prevent visual
obstruction caused by ptosis.
Rehabilitation in cases in which there is a loss of oral
competence presents a challenge. Lack of muscular control
leads to depression of the lower lip, with subsequent
drooling and difficulties with eating. This disability
may be addressed at the time of initial resection
(primary) or at a later date (secondary). Static fixation
with fascia lata or expanded polytetrafluoroethylene
(Gore-Tex; WL Gore & Assoc, Flagstaff, Ariz) has been
described. Harvesting of fascia lata necessitates an incision
on the leg and a second wound site. Expanded polytetrafluoroethylene
slings are a viable option. Excellent
results, with no extrusion, were noted in a series of 24
patients who underwent secondary reanimation, 14 of
whom had undergone prior radiotherapy.1 Infection and
extrusion have been seen in our patient population following
primary expanded polytetrafluoroethylene sling
rehabilitation of the oral commissure and postoperative
radiotherapy. The sling is covered by thin skin with compromised
vascularity from surgical manipulation and radiotherapy.
An effort to develop an improved method of oral
commissure suspension led to the use of freeze-dried acellular
dermis that has been processed to rid the tissue of
viral and immunogenic particles. It is available as dehy-
Figure 1. The acellular dermal (AlloDerm; LifeCell Corp, The Woodlands,
Tex) graft is tunneled subcutaneously. Medially, the graft is split to allow for
attachment to the upper and lower lips.
Figure 2. The acellular dermal (AlloDerm; LifeCell Corp, The Woodlands,
Tex) graft is then anchored and tightened appropriately via a
circumzygomatic permanent suture. A slight elevation of the corner
of the mouth is the desired end point.
Figure 3. Six-month evaluation shows symmetry of the lip. The lip position
has not changed during the postoperative period. Significant overcorrection
is not necessary.
(REPRINTED) ARCH FACIAL PLAST SURG/VOL 3, JAN-MAR 2001 WWW.ARCHFACIAL.COM
56
©2001 American Medical Association. All rights reserved.
drated dermis in varying sizes. After 10 minutes of soaking
in saline, the dehydrated dermis becomes soft and
pliable. No specific immune response is generated, and
revascularization and ingrowth of host cells can be demonstrated.
2 It consistently integrates into native tissue.
Although originally developed for use in burn
patients, acellular dermis has been successfully used in
otolaryngologic procedures. It has been described as a
component of successful septal perforation repair.3 It
also has been used as soft tissue filler and for resurfacing
the intraoral cavity. It effectively replaces a dermal
graft, with few risks. It is ideal in our patient population.
The risks of foreign body reaction, infection, and
extrusion are minimized. It has not stretched with time.
A recent series of 10 patients were described in whom
acellular dermal slings were used for oral commissure
rehabilitation.4 Six (60%) of these patients received
radiotherapy. However, no instances of infection or
extrusion were noted. Nine (90%) of the patients in this
series had excellent or good results with the sling. We
have found that significant overcorrection, such as that
needed with fascia and dynamic slings, is not necessary.
The result has been a complication-free functional and
cosmetic success.
CONCLUSIONS
Reanimation of the face after facial nerve resection is challenging.
Static rehabilitation of the oral commissure with
an acellular dermal sling is described. This technique
should be considered as an alternative for lower face suspension
in cases in which there is a high risk for extrusion
of implant materials.
Accepted for publication May 24, 2000.
Corresponding author: Catherine P. Winslow, MD, Department
of Surgery, Section of Otolaryngology–Facial Plastic
Surgery, Walter Reed Army Medical Center, 6825 Georgia
Ave, Washington,DC20307 (e-mail: [e-mail]).
REFERENCES
1. Biel MA. Gore-Tex graft midfacial suspension and upper eyelid gold-weight implantation
in rehabilitation of the paralyzed face. Laryngoscope.1995;105:876-
879.
2. Wainwright DJ. Use of acellular allograft dermal matrix (AlloDerm) in the management
of full-thickness burns. Burns.1995;21:243-248.
3. Kridel RWH, Foda H, Lunde KC. Septal perforation repair with acellular human
dermal allograft. Arch Otolaryngol Head Neck Surg.1998;124:73-78.
4. Fisher E, Frodel JL. Facial suspension with acellular human dermal allograft. Arch
Facial Plast Surg.1999;1:195-199.
Quotable
Addressed to the students at the University of Toronto, Toronto, Ontario, 1903:
To you is given the harder task of illustrating with your lives the Hippocratic
standards of Learning, of Sagacity, of Humanity, and Probity. Of learning, that
you may apply in your practice the best that is known in our art, and that with
the increase in your knowledge there may be an increase in that priceless
endowment of sagacity, so that to all, everywhere, skilled succour may come
in the hour of need. Of a humanity, that will show in your daily life tenderness
and consideration to the weak, infinite pity to the suffering, and broad
charity to all. Of a probity, that will make you under all circumstances true to
yourselves, true to your high calling, and true to your fellow man.
William Osler
(REPRINTED) ARCH FACIAL PLAST SURG/VOL 3, JAN-MAR 2001 WWW.ARCHFACIAL.COM
57
©2001 American Medical Association. All rights reserved.


Hier mal der Ablauf einer OP. Für den ,den es interessiert.
Schön aus erster Hand zu erfahren , daß AlloDerm so gut funktioniert. Wer sich die PDF-Datei selbst runterlädt , kann sich auch mal die Bilder während und nach der OP anschauen. AlloDerm works.

[skaya]

@neoe
@kubrick
Hi, habt ihr eine Erklärung, warum LIFECELL die letzten Tage so
abgeseift wird?? Die Zahlen waren gut, die Unternehmensführung hat
sich mit den Aussichten nicht zu weit aus dem Fenster gelegt, was ich
persönlich gut finde, nachher können sie die Versprechungen nicht halten.
Beispiele gibt es dafür ja genug.
Vielleicht liegt es ja auch daran, dass Bios momentan nicht so gefragt sind?!
Grüße
Skaya

[Neoe]

Ich denke , du hast das Problem im Wesentlichen selbst erfasst.
Das Problem ist , so paradox es sich anhören mag , daß wir es hier mit einer seriösen Company zu tun haben.
Es wurden im Vorfeld Hoffnungen geschürt , die nicht erfüllbar waren , da Lifecell -und das hätte man aus der Vergangenheit wissen müssen- keine Firma ist , die sich freiwillig in die Nesseln setzt.
Jetzt bedanken sich einige bei den Dummköpfen , die sich ins Boxhorn jagen lassen und sammeln auf billigem Niveau ein.

Irgendwie bin ich schon ein bißchen sauer. Einerseits reden die ganzen Deppen davon , daß gerade solche Sachen wie Enron zur derzeit lauen Börse beitragen , aber andererseits straft man eine solide geführte Firma ab , die zudem noch in einem zukunftsträchtigen Bereich arbeitet.
Nichts , aber auch gar nichts , von dem was Lifecell in den letzten Monaten , eher schon Jahren , angekündigt hat , wurde verfehlt.

Letztendlich ist es mir egal; ich habe den fulminanten Anstieg mitgemacht , ich werde den Verfall miterleben und mit 100%-iger Sicherheit kommt hier auch wieder der Upmove.

[Neoe]

Schmerz laß nach!!! Ich fass es nicht, wie man eine Aktie mit permanenten 100er Orders zum Absturz bringen kann.
Bei einem Volumen von 85,000 Aktien.
Spielt hier einer mit sich selbst?

[Kubrick2001]

Hallo Skaya,
Ich denke der Kursverfall läßt sich durch den Ausblick auf 2002 erklären. Die meisten Shareholder haben wahrscheinlich mit einem höheren Gewinn als 5 Cent gerechnet. Des weiteren wurde als Einführungstermin von neuen Produkten "vielleicht 2002" genannt. Das war den meisten zu ungenau.
Außerdem darf man auch nicht vergessen, daß nur wenige Investoren bisher mit Lifecell Geld verdient haben. Vor 10 Jahren z.B. wurde Lifecell noch bei $13.50 gehandelt. Ich weiß nicht wie lange der Kurs jetzt noch fällt, denke aber das bei $2 ein ziemlich stabiler Boden sein müßte. Ich persönlich habe heute 2/3 meiner Lifecell Aktien verkauft und werde bei drehen des Kurses zurückkaufen.

Schöne Grüße
Kubrick

[Kubrick2001]

Hier die Meinung von Toppedout aus dem Yahoo-Board, welche ziemlich genau meine eigene wiedergibt.

"Sold my postion at $3.30, I did not like the way it was trading. I still like the fundamentals here. I will buy back soon. "


mfg Kubrick

[HundVincent]

Hallo

Ich habe nun ein wenig die hiesige Diskussion um LIFC verfolgt und fange mit diesem Posting mal an, mich zu beteiligen.

Mittlerweile bin ich nach kurzfristigen starken Buchgewinnen wieder im Minus. Das ist an sich nicht so schlimm, worüber ich mir aber z. Z. (wie alle anderen wohl auch) nicht im Klaren bin, ist, wie die nähere Zukunft der Aktie aussehen wird:
M. E. handelt es sich bei Lifecell um ein tatsächlich gutes Unternehmen, das nach herkömmlichen Bewertungsmaßstäben auch nicht zu hoch bewertet ist. Sicherlich war die Aufwärtsbewegung ab Anfang Januar in ihrer Stärke (retrospektiv) übertrieben, allerdings gilt dies nun auch für den ab Bekanntgabe der Zahlen eingesetzte Abwärtssog von mittlerweile etwa 30 % seit der Spitze. Jedenfalls war ein Grund dafür das „sell on good news“-Motto (good news = break even), aber waren die Zahlen denn wirklich so gut ?
Natürlich ist ein kleines Unternehmen wie Lifecell i. d. R. höheren Volatilitäten ausgesetzt, aber einen solcheAbschlag kann ich nicht recht verstehen, es sei denn, irgend etwas mir Unbekanntes veranlasst die Investoren zum Verkauf. Ich hoffe, dass es eine solche Unbekannte nicht gibt, aber einen Einbruch, der bald sämtliche Kursgewinne aufgezehrt hat, die seit Bekanntgabe des break evens Ende letzten /Anfang dieses Jahres aufgebaut wurden, sehe ich nicht als gerechtfertigt an, wenn die sonstige Situation des Unternehmens sich nicht verändert hat. Zu klären ist dann auch, warum der Tailwind-Fonds so massiv ausgestiegen ist und wann der dadurch verursachte Abgabedruck aufhört.

Es scheint mir vieles klärungsbedürftig, doch gerade wegen der Stärke der Korrektur sollte man sich überlegen, nicht wenigstens mit einer kleinen Position wieder einzusteigen, um eine eigentlich zu erwartende technische Gegenreaktion, vor allem aber die (sollte nichts faul sein) fundamental eigentlich ausgezeichneten Perspektiven der Aktie zu nutzen.

Was meint Ihr ?

Gruß

Vincent

[Neoe]

HundVincent@:
Ich bleibe meiner Position treu. Ich denke , daß hier absolut nichts faul ist. Ich sehe das Problem wirklich in der nüchternen , aber realistischen Berichterstattung von Lifecell (conference call) ; inwieweit die Aktie bei ca. 3,5$ überbewertet war , kann ich nicht sagen. Im Vergleich zu ihren Konkurrenten war sie es auf keinen Fall.

Der einzige Grund für den Absturz, den ich noch als fundamental bedingt akzeptieren würde , wäre die Tatsache ,daß bisher kein Partner für den Vertrieb der orthopädischen Produkte gefunden wurde.
Ansonsten ist Lifecell bei der Aussage geblieben , daß 2002 neue Bereiche erschlossen werden.

Die Ansicht , daß man einen höheren Gewinn erwartet und deswegen die Aktie jetzt abstraft , sehe ich als Unsinn an.
In jeder Analyse über Lifecell wird darauf hingewiesen , daß die Sache eigentlich erst wirklich ins Rollen kommt , wenn die neuen Produkte auf dem Markt sind. Das man von der "Haut" allein nicht ewig überleben wird , ist klar.
Aber -30% aufgrund von Ungeduld geht mir etwas zu weit.

[skaya]

@Neoe
@kubrick2001
Hi, vielen Dank für Eure Rückmeldungen/Meinungen.
Ich denke, wir werden in den folgenden Wochen und Monaten
wieder bessere Zeiten sehen.
Ich behalte jedenfalls meine Aktien und werde ggf. welche dazukaufen.
Viele Grüße
Sakya

[Neoe]

Scheint als hätten wir das Fiasko überstanden.

Letzter Handel:2,80$
ASK:2,80$
BID:2,74$

Da fällt mir zumindest vorerst ein Stein vom Herzen.

[Neoe]

Gestern nach Börsenschluß schon wieder 22,000 gehandelt. Das war über ein Viertel des gesamten Handelsvolumens. Ich glaube der Tail Wind Fund hat seine Mission immer noch nicht vollendet.
Der Kurs scheint sich trotz allem wieder stabilisiert zu haben.

[bagg]

Hallo Leute,
lifecell geht heute durch die Decke und ich
finde keine News. Kann mir einer von euch
sagen was da los ist.

mfg bagg

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Ha , ha , keiner merkt es und wir sind wieder über 3,5 $ , daß ging doch recht schnell.
Sattes Plus heute , mal gespannt was dahinter steckt.
Vielleicht ein Vertriebspartner für die orthopädischen Produkte?
Oder hat man in den letzten Wochen einfach nur ein paar Leute heftig abgezockt?
Ich hab wie gesagt kein Stück hergegeben.

[Neoe]

Sorry , da muß ein kleines Problem vorliegen. Ich wollte euch keine Gehirnwäsche verabreichen.

[Neoe]

Unter "coverage reiterated" gibt es ein outperformer rating für LIFC:
http://www.briefing.com/FreeServices/fs_updown.htm

[Neoe]

Außerdem macht das Gerücht die Runde , daß CBS einen Bericht im Petto hat.

[drpaulo2001]

Hallo jungs, bin seit Montag dabei.Habe mir 20000 stück gekauft.Denke die nächste Woche sehen wir die 4usd,oder was meint ihr .Selbst wen sie in 1Jahr auf ihrem alten Höchstand ist ,ist es auch ok.Sagt mir eure meinung zu lifecell.drpaulo2001

[diwa]

@ alle

hat jemand eine Ahnung wieso der Kurs nachbörslich bei einem Umsatz von 70.000 Stück auf $2,63(bigcharts.com)nachgegeben hat. Das sind beinahe 20% und ich kann keine News finden.

Danke

Dietmar

[Neoe]

Vielleicht war der Anstieg im Laufe des Tages im Interesse desjenigen , der nachbörslich die 70,000 verschachert hat.
Sonst wäre es nachbörslich eventuell noch weiter runter gegangen.
Es dürfte wohl der Tail Wind Fund gewesen sein.

[Neoe]

ABC hat LIFC nun gefeatured. Gespannt wie die Reaktion ausfällt. Anscheinend kam Lifecell gut rüber.
Wer es sich mal anschauen möchte(hatte selbst leider noch keine Zeit),hier die Adresse:
www.businessnow.com Click on Lifecell streaming video.

Vorbörslich scheint es zu wirken:

ASK 3,45
BID 3,44

[Neoe]

Auf Tageshoch geschlossen (3,6$) und das Börsenumfeld scheint freundlich zu bleiben.
Das könnte ein weiterer Schritt zu einem längerwährenden Aufstieg sein.
Wenn jetzt noch was zu einem neuen Produkt zu hören wäre , müßten die Kursziele dramatisch erhöht werden.
Bleibt festzuhalten , daß die Leute endlich schnallen , daß hier ein großes Ding auf uns zukommt.
Der meiner Meinung nach konservative Ausblick für dieses Jahr hat außerdem den Nährboden für dauerhafte , positive Überraschungen bereitet.
Ihr werdet es schon sehen....

[Neoe]

Das 10-K-Filing:



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


FORM 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF
THE SECURITIES EXCHANGE ACT OF 1934

FOR THE FISCAL YEAR ENDED DECEMBER 31, 2001 COMMISSION FILE NUMBER: 0-19890

LIFECELL CORPORATION
(Exact name of registrant as specified in its charter)

DELAWARE 76-0172936
(State or other jurisdiction of (I.R.S. employer
Incorporation or organization) identification no.)

ONE MILLENNIUM WAY
BRANCHBURG, NEW JERSEY 08876
(Address of principal executive offices, including zip code)

[phone]
(Registrant`s telephone number, including area code)




SECURITIES REGISTERED PURSUANT TO SECTION 12(B) OF THE ACT:

NONE

SECURITIES REGISTERED PURSUANT TO SECTION 12(G) OF THE ACT:

COMMON STOCK, PAR VALUE $.001 PER SHARE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes X No



--------------------------------------------------------------------------------

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant`s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [ ]

The aggregate market value of the voting stock (Common Stock and Series B Preferred Stock, assuming conversion of such Preferred Stock into Common Stock at the current conversion rate) held by non-affiliates of registrant as of March 15, 2002: $67,613,000.

Number of shares of registrant`s Common Stock outstanding as of March 15, 2002:
21,042,868. (If the Series B Preferred Stock had converted into Common Stock as of such date, there would be 23,998,240 shares of Common Stock outstanding.)


DOCUMENTS INCORPORATED BY REFERENCE:
Portions of registrant`s definitive proxy statement to be issued in conjunction with registrant`s annual stockholders` meeting to be held on May 31, 2002 have been incorporated by reference into Part III hereof.




--------------------------------------------------------------------------------

TABLE OF CONTENTS

DESCRIPTION

Item Page
--------------------------------------------------------------------------------

PART I
Item 1. Business 3
General 3
Technology 3
Strategy 5
Products and Product Development Activities 6
Marketing 10
Sources of Materials 10
Government Regulation 11
Research and Development 14
Patents, Proprietary Information & Trademarks 15
Competition 15
Employees 16
Risk Factors 16
Special Note Regarding Forward-Looking Statements 23
Item 2. Properties 24
Item 3. Legal Proceedings 24
Item 4 Submission of Matters to a Vote of Security Holders 24

PART II
Item 5. Market for the Registrant`s Common Equity and Related
Stockholder Matters 25
Dividend Policy 25
Item 6. Selected Financial Data 26
Item 7. Management`s Discussion and Analysis of Financial
Condition and Results of Operations 27
General and Background 27
Critical Accounting Policies 27
Results of Operations 27
Liquidity and Capital Resources 29
Item 7A Quantitative and Qualitative Disclosure About Market Risk 31
Item 8. Financial Statements and Supplementary Data 31
Item 9. Changes and Disagreements with Accountants on Accounting
and Financial Disclosure 31

PART III
Item 10. Directors and Executive Officers of the Registrant 32
Item 11. Executive Compensation 32
Item 12. Security Ownership of Certain Beneficial Owners and Management 32
Item 13. Certain Relationships and Related Transactions 32

PART IV
Item 14. Exhibits, Financial Statement Schedules, and Reports on Form 8-K 33






--------------------------------------------------------------------------------


PART I
This Annual Report on Form 10-K contains, in addition to historical information, "forward-looking statements" (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties. See "Business-Special Note Regarding Forward-Looking Statements."


ITEM 1. BUSINESS

GENERAL

We develop and market biologically based solutions for the repair and replacement of damaged or inadequate human tissue in numerous different clinical applications. Our core tissue matrix technology removes all cells from the tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. We currently market four human tissue based products: AlloDerm(R) for plastic reconstructive, burn and periodontal procedures; Cymetra(TM), a version of AlloDerm(R) in particulate form for non-surgical correction of soft tissue defects; Repliform(TM), a version of AlloDerm(R) for urology and gynecology procedures; and cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns. Our development programs include the potential application of our tissue matrix technology to vascular, nerve and orthopedic tissues; investigation of human tissues as carriers for therapeutics; ThromboSol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion.

We were incorporated in the State of Delaware in 1992 as the successor to a Delaware corporation that was incorporated in 1986. Our address is 1 Millennium Way, Branchburg, New Jersey 08876 and our phone number is [phone].

TECHNOLOGY

To date our product development programs have been generated from the following proprietary technologies:

- methods for producing an extracellular tissue matrix by removing antigenic cellular elements while stabilizing the matrix against damage;

- methods for cell preservation by manipulating cells through signal transduction (i.e., manipulation of cellular metabolism) to protect cells during prolonged storage; and

- methods for freeze-drying biological cells and tissues without the damaging effects of ice crystals.


TISSUE MATRIX TECHNOLOGY
Our tissue matrix technology removes antigenic cells from the tissue matrix to eliminate the potential for specific rejection of the transplanted tissue. Our tissue matrix technology also:

- stabilizes the tissue matrix by preserving its natural structure and biochemical properties that promote cell repopulation; and

- allows for extended storage by freeze-drying the tissue matrix without significant ice crystal damage thus avoiding a non-specific immune response upon transplantation.

Soft tissue contains a complex, three-dimensional structure consisting of multiple forms of collagen, elastin, proteoglycans, other proteins, growth factors and blood vessels (the "tissue matrix"). Together, the tissue matrix and the cells that populate it form the soft tissues of the body, such as dermis, heart valves, blood vessels, nerve connective tissue, and other tissue types. As part of the body`s natural remodeling process, cells within a tissue continuously degrade and, in the process, replace the tissue matrix. However, in the event that a large portion of the tissue matrix is destroyed or lost because of trauma or surgery, the body cannot regenerate the damaged portion. The only method of replacing large sections of the tissue matrix is through transplantation.


3

--------------------------------------------------------------------------------
Soft tissue transplants from one part of the patient`s body to another ("autograft") generally are successful; however, the procedure results in the creation of an additional wound site. Historically, the ability to transplant tissue from one person to another ("allograft") has been limited because the donor`s cells within the transplanted tissue may trigger an immune response, resulting in rejection of the transplanted tissue. We believe that previous attempts to remove cells from soft tissue grafts before performing an allograft transplant have resulted in disruption or damage of the tissue matrix, causing an inflammatory response and rejection of the tissue following transplantation.
We believe our tissue matrix technology offers the following important benefits:

Natural Tissue Regeneration. Tissue grafts produced with our tissue matrix technology retain the structural and biochemical properties that stimulate normal cell repopulation and normal soft tissue regeneration. In addition, in our clinical studies with dermis and preliminary animal studies with heart valve leaflets, nerve connective tissue grafts, and vascular grafts processed using our technology we have shown that such tissues can be remodeled by the recipient`s own cells and eventually become the recipient`s own tissue.

Multiple Potential Applications. We believe that our tissue matrix technology has the potential to generate additional products with multiple applications. In addition to the current commercial applications of AlloDerm, Repliform and Cymetra, we believe that these products may provide additional benefits in other clinical applications. We also are evaluating the applicability of our technology to process other human tissues and are conducting pre-clinical studies with vascular and orthopedic tissues.

Safety. Our tissue matrix technology yields products that can revascularize and integrate into the body`s own tissues thereby allowing the patient`s immune cells to penetrate into the transplanted tissue and thus aid in preventing infections. In contrast, certain synthetic implants do not allow penetration of the patient`s immune cells, thereby compromising the body`s natural ability to fight infections. Our processed human tissue products have a proven safety record of over nine years and over 200,000 tissue grafts processed and distributed to date.

Prolonged Shelf Life. Our tissue matrix technology allows extended storage and ease of transportation of products. AlloDerm and Repliform have been tested for storage at normal refrigerated temperatures for up to two years. In contrast, traditionally processed skin allografts require low temperature (-80 C) storage and shipping with dry ice. Cymetra is stored at normal refrigerated temperatures for up to one year.

Compatibility with Other Technologies. Human tissues processed with our technology retain important biochemical components, such as proteoglycans including hyaluronic acid. These biochemical components bind growth factors and cells that stimulate tissue regeneration. Therefore, we believe it may be possible to use our technology to develop tissue-based delivery vehicles for these factors and cells.


CELL PRESERVATION TECHNOLOGY
Blood cells circulating within the body are exposed to multiple factors that maintain their stability and/or prevent spontaneous clotting. When blood cells are removed from the body for storage, these stabilizing influences are absent and result in the destabilization and/or irreversible spontaneous clotting of the cells. These damaging events currently limit the shelf life of transfusable red blood cells to 42 days under refrigeration and blood platelets to five days at room temperature.

Through our research efforts, we have developed cell preservation technology mimics the stabilizing influences present in the body through manipulation of signal transduction mechanisms that control cellular metabolism, combined with either low temperature storage or our patented freeze-drying technology. If successfully implemented, our cell preservation technology could result in multiple products for the preservation of directly transfusable blood cells with extended shelf life, which could be stored in a manner consistent with current blood banking practices.


4

--------------------------------------------------------------------------------
STRATEGY
Our strategy is to be a leader in developing and marketing biologically based solutions for the repair and replacement of damaged or inadequate human tissue in numerous clinical applications. Our strategy includes the following principal elements:


EXPANDING PENETRATION OF ALLODERM INTO CURRENT TARGET MARKETS
Our direct marketing effort focuses on the use of AlloDerm in head and neck and plastic reconstructive procedures and general surgery. We see great opportunity for revenue growth in this area, in which AlloDerm is used as an alternative to the current standard of care, autografts. We have initiated numerous programs to achieve this goal. These include:

- conducting additional clinical studies to demonstrate the benefits of AlloDerm compared to autografts;

- supporting publications in leading scientific journals describing the uses and benefits of AlloDerm;

- utilizing our direct sales and marketing organization to call on a broader audience of hospital-based surgeons;

- sponsoring educational and surgical training workshops on the use of AlloDerm; and

- participating at trade shows.

We currently market AlloDerm for use in head and neck and plastic reconstructive procedures, burn surgery and general surgery in domestic markets through our own direct sales force. For periodontal applications and selected international markets, we market through distributors.


EXPANDING PENETRATION OF REPLIFORM IN UROGYNECOLOGY MARKET
Repliform, introduced in 1999, is a version of AlloDerm for applications in the urology and gynecology markets. We market Repliform through Boston Scientific Corporation, a worldwide developer, manufacturer and marketer of medical devices with a well-established marketing presence in the urology field.

In February 2000, we, in conjunction with Boston Scientific Corporation, initiated the full launch of Repliform following the successful completion of a targeted introduction of the product to thought leaders in the United States. We intend to increase the penetration of Repliform in this market by demonstrating the benefits of Repliform compared to other products when used as a bladder sling for the treatment of urinary incontinence and for the repair of pelvic floor defects.


EXPANDING PENETRATION OF CYMETRA IN RECONSTRUCTIVE PLASTIC AND DERMATOLOGY
MARKETS
In December 1999, we introduced Cymetra, a version of AlloDerm in a particulate form for non-surgical correction of soft tissue defects, to selected plastic and reconstructive surgeons. In June 2000, we, in conjunction with OMP, Inc., initiated the full commercial launch of Cymetra to office-based plastic surgeons and dermatologists.


LEVERAGING OUR TECHNOLOGY PLATFORMS TO DEVELOP NEW PRODUCTS
We continue to investigate the application of our matrix technology to the regeneration of other human tissues including vascular, orthopedic and nerve tissues.

The application of our tissue matrix technology to vascular tissues has shown promise in pre-clinical feasibility studies. In October 2001, we received final approval for a $2.1 million research grant from the Department of Defense, through the U.S. Army Medical Research Acquisition Activity, to investigate the application of our technology to the regeneration of vascular and nerve tissues. We retain all rights to commercialize products resulting from this collaboration. We are commencing pre-clinical studies focused on using umbilical vessels as the source graft. Upon successful completion of these studies, we plan to commence our first clinical evaluation using a human tissue based vascular graft.

Pre-clinical studies conducted by us suggest that our acellular tissue matrix may also remodel into tendons, cartilage and bone. In October 2000, we received final approval for a $2.3 million research grant from the Department of Defense, through the U.S. Army Medical Research Acquisition Activity, to


5

--------------------------------------------------------------------------------
investigate the application of our technology to the regeneration of orthopedic tissues. We retain all rights to commercialize products resulting from this collaboration. In 2001, we commenced pre-clinical studies to investigate the ability of acellular tissue matricies to remodel into various orthopedic tissues. Upon successful completion of these studies, we plan to commence our first clinical evaluation using human tissue based grafts.
We are also using our proprietary cell preservation technology in the development of solutions that would extend the shelf life of platelets and red blood cells. In February 2002, we received final approval of an $824,000 research grant from the Office of Naval Research to investigate the potential to preserve red blood cells through freeze drying. We retain all rights to commercialize products resulting from this collaboration. Additionally, we may decide to establish collaborative out-licensing arrangements with appropriate partners to fund the development and commercialization of certain of these products.

PRODUCTS AND PRODUCT DEVELOPMENT ACTIVITIES


ACELLULAR TISSUE PRODUCTS

ALLODERM
AlloDerm is acellular tissue processed with our tissue matrix technology using donated human cadaveric skin. We believe that AlloDerm is the only human tissue product on the market today that supports the regeneration of normal human soft tissue. Following transplant, our AlloDerm graft becomes repopulated with the patient`s own cells and is revascularized (i.e., blood supply is restored), becoming engrafted into the patient. AlloDerm is a versatile tissue and has multiple surgical applications. AlloDerm is predominately used in plastic reconstructive procedures, burn surgery, periodontal surgery and general surgery.

We receive donated human cadaveric skin from tissue banks and organ procurement organizations in the United States that comply with the United States Food and Drug Administration (the "FDA") human tissue regulations. In addition, we require supplying tissue banks and organ procurement organizations to comply with procedural guidelines outlined by the American Association of Tissue Banks. We conduct microbiological and other rigorous quality assurance testing before our acellular human tissue products are released for shipment. AlloDerm is shipped at ambient temperature by overnight delivery services and has a two-year refrigerated shelf life.

We have established what we believe to be adequate sources of donated skin tissue at acceptable costs to satisfy the foreseeable demand for all of our commercialized tissue products. However, there can be no assurance that the future availability of donated human cadaveric skin will be sufficient to meet our demand.

PLASTIC RECONSTRUCTIVE SURGERY. AlloDerm is marketed to plastic reconstructive surgeons as an "off-the-shelf" alternative to autograft. Within plastic reconstructive surgery, AlloDerm is used in various head and neck and reconstructive surgeries, cancer reconstruction, scar revision and oral cavity reconstruction surgical procedures:

- as an implant for soft tissue reconstruction or tissue deficit correction;

- as an interpositional graft for tissue coverage or closure;

- as a graft or implant for scar revision or the dermal component of a skin graft;

- as a sling to support tissue following nerve or muscle damage; and

- as a tissue patch to restore closure.

In these procedures, the greatest competitive pressures to AlloDerm are from autologous tissue and synthetic and biosynthetic materials. We believe the disadvantages of using autologous tissue is the creation of a separate donor site wound and the associated pain, healing, and scarring from this additional wound. Additionally, we believe the disadvantages of using synthetic materials are the susceptibility of synthetics to infection, the graft moving away from the transplanted area (mobility), and erosion of the graft through the skin (extrusion). Some biosynthetic materials may include bovine collagen, which requires patient sensitivity testing.


6

--------------------------------------------------------------------------------
BURNS. During 1994, we commenced marketing of AlloDerm for use in the treatment of third-degree and deep second-degree burns requiring skin grafting. Skin is the body`s largest organ and is the first line of defense against invasion of foreign substances. It contains two functional layers, the upper surface consisting primarily of cells (epidermis) and an underlying foundational layer consisting primarily of extracellular matrix proteins and collagen (dermis). The epidermis functions as a water barrier and maintains hydration. The dermis provides other important skin properties including tensile strength, durability and elasticity. Dermis, like many other tissues of the body, is not capable of de novo regeneration. The most conservative and common surgical treatment of third-degree and deep second-degree burns use split-thickness skin autografts (the epidermal layer and a portion of the dermis) taken from uninjured areas of the patient`s body. The surgical procedure when using AlloDerm in treating these patients is to place AlloDerm where the patient is missing dermis and cover the AlloDerm with an ultra-thin split-thickness skin autograft (the epidermal layer and a much thinner portion of the dermis). This procedure has produced comparable results to normal thickness autografts while significantly reducing donor site trauma.
The use of AlloDerm in burn grafting has clinically shown performance equivalent to autograft in reducing the occurrence and effects of scar contracture. Scar contracture is a progressive tightening of scar tissue that can cause joint immobility. Severe scar contracture can limit the use and function of all mobile joints, such as the arms, legs, feet, hands and neck. Burn patients commonly need repetitive reconstructive surgeries for scar contracture. We believe that AlloDerm provides significant therapeutic value when used in burn grafting over a patient`s mobile joints.

PERIODONTAL SURGERY. We began marketing AlloDerm to periodontists in September 1995. BioHorizons Implant Systems, Inc. is our exclusive distributor of AlloDerm for use in periodontal applications in the United States and certain international markets. Periodontal surgeons use AlloDerm to increase the amount of attached gum tissue supporting the teeth. Until the development of AlloDerm, these procedures were predominately performed with autologous connective tissue grafts excised from the roof of the patient`s mouth and then transplanted to the gum.

Multiple independent prospective clinical trials have demonstrated that AlloDerm is equivalent to autologous connective tissue grafts for root coverage. This procedure involves placing AlloDerm underneath gum tissue, which is then lifted up to cover the exposed root. AlloDerm allows for the coverage of multiple exposed roots in a single surgery without being limited by the availability of autologous palatal tissue.

AlloDerm tissue products also are used as barrier membranes in guided bone regeneration. In this function, the AlloDerm tissue serves as a barrier over allograft bone grafts or bone substitutes, which are used to restore degenerated alveolar bone.

Competitive procedures use autologous tissue as well as synthetic material. We believe that AlloDerm has advantages over autologous tissue because of the reduced trauma to the patient, and over certain non-resorbable synthetic materials because it integrates into the patient`s tissue and does not require a separate procedure for removal.

POTENTIAL ORTHOPEDIC APPLICATIONS OF ALLODERM. Pre-clinical studies conducted by us have indicated that AlloDerm and Cymetra may have the potential to remodel into certain types of orthopedic tissues. Based on these preliminary results, we commenced a product development program for orthopedic applications of AlloDerm and Cymetra and we intend to conduct additional studies investigating the potential of these tissue products to remodel into orthopedic tissues such as tendon, ligament, cartilage, meniscus and bone. We are also investigating the potential of applying our tissue matrix technology to certain orthopedic tissues such as tendons and ligaments.


REPLIFORM
UROLOGY AND GYNECOLOGY SURGERY. Repliform is the trade name given to AlloDerm when it is labeled for the intended use of repairing damaged or inadequate integumental connective tissue in urology and gynecology surgical procedures. Since 1997, surgeons have used AlloDerm in urology and gynecology procedures as a bladder sling in the treatment of urinary incontinence and for the repair of pelvic floor defects. Boston Scientific Corporation is our exclusive worldwide sales and marketing representative for Repliform for use in urology and gynecology.

Fewer than half of the individuals affected by urinary incontinence seek treatment due to the combined factors of embarrassment and a lack of acceptable therapeutic options for some types of incontinence. Some forms of female stress


7

--------------------------------------------------------------------------------
urinary incontinence can be treated with a sling procedure, which involves lifting and supporting the bladder neck to provide urethral support and compression.
Cystocele, rectocele and other pelvic floor conditions also occur frequently in women and require soft tissue surgical repair. These conditions are particularly common after multiple vaginal births and cause significant discomfort to the patient. It is common that these conditions exist with or cause urinary incontinence. Therefore, it is becoming the current standard of care to correct pelvic floor conditions at the same time as a sling or suspension procedure to ensure that there are no conditions that can adversely affect patient outcome.

Currently, materials used for slings and pelvic floor repair surgeries include autologous tissue, synthetic materials and cadaveric fascia. The autologous tissue often is taken from the patient`s thigh or abdomen resulting in a painful donor site. The greatest drawback of using synthetic materials is the occurrence of erosion through the urethra or vaginal wall causing pain and infection, necessitating repeat surgery. We believe that Repliform used as a sling provides a safe and effective alternative that eliminates the need for a donor site, will repopulate as the patient`s own tissue and will not erode through the soft pelvic tissues.


MICRONIZED ALLODERM(R) PRODUCTS

CYMETRA
Cymetra, the brand name for Micronized AlloDerm(R) is made from AlloDerm sheets that are micronized at a low temperature to create a particulate form of AlloDerm suitable for injection. This form allows a non-surgical alternative in reconstructive plastic and dermatological procedures to replace damaged or inadequate skin tissue, such as correction of soft tissue defects and depressed scars or to replace integumental tissue lost through atrophy.

In June 2000, we, in conjunction with OMP, Inc., initiated the full commercial launch of Cymetra to office-based plastic surgeons and dermatologists.

We believe that Cymetra offers a new non-surgical alternative in reconstructive and plastic dermatological procedures. This represents a significant market opportunity for Cymetra as it does not require sensitivity testing and similar to AlloDerm promotes the regeneration of normal human soft tissue.

We also believe that Micronized AlloDerm may have urological uses such as for the treatment of urethral sphincter deficiency, a common cause of urinary incontinence, and vesicoureteric reflux, which is the most common cause of renal failure in children. One treatment for these conditions has been injecting bovine collagen to bulk the sphincter muscle or to recreate the proper angle of the urethra or the ureter. We currently are testing the persistence of micronized acellular tissue in animals for the treatment of urological disorders.


FDA STATUS OF ALLODERM, REPLIFORM AND CYMETRA
The FDA generally permits tissue classified as human tissue for transplantation to be commercially distributed without obtaining prior FDA approval. In 1996, AlloDerm was reviewed by the FDA and found to be human tissue for transplantation when intended for the replacement or repair of damaged or inadequate integumental tissue, including gingival dermis. On that basis, we continued commercial distribution of AlloDerm for plastic reconstructive, burn, and periodontal surgery. Repliform is the trade name given to AlloDerm when it is labeled for the intended use of repairing damaged or inadequate integumental connective tissue in urological and gynecological surgery. Cymetra is Alloderm that has been micronized at a low temperature into injectable powder form. This form of AlloDerm permits delivery to subcutaneous locations by injection rather than open surgery to repair damaged or inadequate integumental tissue. The micronized particles are biochemically identical to AlloDerm. In November 2000, the FDA wrote to us and requested detailed information about Repliform and Cymetra, including copies of existing labeling and advertising, a description of product composition and processing, and other information supporting LifeCell`s belief that each of these products satisfy the requirements of human tissue for transplantation. In February 2001, we provided a detailed submission responding to the FDA`s request. In June 2001, we received a letter from the FDA indicating that Repliform and Cymetra, as currently marketed, meet the definition of human tissue for transplantation.


8

--------------------------------------------------------------------------------

CARDIOVASCULAR TISSUE PRODUCTS
We are commencing pre-clinical studies to evaluate human tissue based small-diameter vascular graft products for potential use in cardiovascular surgery. If successfully developed, a human tissue based vascular graft could be used in coronary artery bypass procedures or used to restore peripheral blood circulation in patients with peripheral vascular disease, such as below-knee bypass procedures. According to an independent market research report and published articles, annually in the United States replacement vascular conduits are required for 375,000 coronary artery bypass surgeries and 230,000 peripheral vascular reconstructions. There are additional requirements for construction of arterio-venous (A-V) fistulas for vascular access in hemodialysis, patches for closure following carotid endarterectomy and microvascular conduits for microsurgical repair techniques.

Veins and arteries harvested from the patient for use as a replacement graft continue to be the mainstay of therapy, yet these vessels are frequently donor site limited as a result of the condition of the patient. When available, autologous vessel harvest leads to significant patient discomfort and an increase in risk for complications. To address these drawbacks, we believe there is a severe requirement for an "off-the-shelf" small diameter vascular graft, which is non-immunogenic, non-thrombotic and has compliance characteristics and handling properties equivalent to native vessels.

We have demonstrated in a pre-clinical study that a graft processed by us had an equivalent patency to the animal`s fresh autologous vein. This study also showed the graft was repopulated with the animal`s own cells and hence, remodeled into the animal`s own tissue. We are currently conducting additional pre-clinical studies.


BLOOD CELL PRESERVATION
We are developing ThromboSol platelet storage solution to extend the shelf life of transfusable platelets and other methods to extend the shelf life of red blood cells, white blood cells and stem cells.

THROMBOSOL We are developing ThromboSol; a patented biochemical formulation designed to protect transfusable platelets from damage during storage at low temperatures. The expected use of the product would be by blood banks to increase the safety and extend the shelf-life of transfusable platelets, thereby increasing the supply of available platelets, as well as to store autologous platelets in advance for individuals expecting to undergo surgery or chemotherapy.

Platelets are blood cells that initiate clotting. Untreated platelets are sensitive to storage at low temperatures and cannot be refrigerated effectively. Presently, platelets are stored at room temperature and, due to the risk of microbial contamination, have a limited shelf life of five days. We have shown in laboratory tests that the addition of ThromboSol solution preserves the in vitro functional aspects of refrigerated platelets for up to nine days and frozen platelets for more than two years. During 1999, we successfully completed biocompatability testing on the ThromboSol solutions. A pilot clinical study under a physician-sponsored Investigational New Drug Application ("IND") was conducted during 1998 and the study found that ThromboSol treated cryopreserved platelets performed better than standard cryopreserved platelets. A second physician-sponsored IND was performed which involved a "standard of care" transfusion of ThromboSol cryopreserved platelets into oncology patients. This study was completed in 2001 and demonstrated that Thrombosol preserved platelets performed equivalent to fresh platelets. Further clinical evaluation is continuing. Any product developed will require extensive regulatory approvals prior to marketing in the United States. Our development efforts to date have primarily been funded through research grant funds from the Department of Defense.

RED BLOOD CELLS We are conducting research to develop procedures to freeze and freeze-dry red blood cells. Such technology would be used by blood banks for long-term storage of donated units of red blood cells, extending the available blood supply, and for storage of autologous red blood cells for individuals expecting to require blood transfusions as part of planned surgery.

Red blood cells currently may be stored up to 42 days under refrigeration. Current procedures to freeze red blood cells require the use of cryoprotectant solutions that are toxic to the recipient and must be removed by washing the cells prior to transfusion. This removal procedure is labor-intensive and requires the immediate transfusion of the thawed and washed blood. We believe that the successful development of non-toxic low temperature methods of storage could simplify the use of frozen blood and potentially allow widespread storage of autologous blood.


9

--------------------------------------------------------------------------------
Any product developed will require extensive regulatory approvals, including approval of an IND by the FDA to conduct clinical trials. Our development efforts to date have primarily been funded through research grant funds from the Department of Defense.
MARKETING

We currently distribute AlloDerm in the United States for plastic reconstructive, burn and general surgical applications through our network of direct technical marketing representatives. In March 1999, we entered into an exclusive agreement with Boston Scientific Corporation for the worldwide marketing of Repliform for use in urology and gynecology. In February 2000, we entered into an exclusive agreement with OMP, Inc. for promotion of Cymetra to office-based dermatologists and plastic surgeons in the United States and certain international markets. In August 2000, we entered into an exclusive agreement with BioHorizons Implant Systems, Inc., granting them distributor rights in the United States and select international markets of AlloDerm for use in periodontal applications.

Prior to 1999, we used a network of domestic and international distributors to augment our sales efforts. We currently maintain a network of international distributors, but during the first quarter of 1999, we eliminated the use of domestic distributors except for the distribution of AlloDerm for periodontal applications.

As of March 1, 2002, we had sales and marketing staff of 37 persons, including 28 domestic sales personnel, and 9 domestic marketing and other personnel. Our sales representatives are responsible for interacting with ear, nose and throat surgeons, plastic surgeons, burn surgeons and general surgeons and educating them regarding the use and anticipated benefits of AlloDerm and Cymetra. We also participate in numerous national fellowship programs, national and international conferences and trade shows and participate in, or fund certain educational symposia.

SOURCES OF MATERIALS

In 2001, we obtained all of our donated human cadaveric tissue from 23 tissue banks and organ procurement organizations in the United States. We estimate that there are at least 100 tissue banks and organ procurement organizations in the United States. In January 2002, we entered into an agreement with LifeNet, the largest organ procurement based tissue bank in the United States. Under the terms of the agreement, LifeNet will supply donated human cadaveric skin tissue to us for processing into cryopreserved skin and AlloDerm tissue products on a priority basis for burn victims.

We believe we have established adequate sources of donated human tissue to satisfy the expected demand for our products in the foreseeable future. Although we have not experienced any material difficulty in procuring adequate donated cadaveric skin tissue, there is risk that the future availability of donated human skin will not be sufficient to meet our demand. We compete with other entities that process and or distribute allograft skin and other human tissues.

Procurement of certain human organs and tissue for transplantation is subject to the restrictions of the National Organ Transplant Act ("NOTA"), which prohibits the acquisition of certain human organs, including skin and related tissue for valuable consideration, but permits the payment of reasonable expenses associated with the procurement, transportation, processing, preservation, quality control and storage of human tissue and skin. We reimburse tissue banks for expenses incurred that are associated with the recovering and transportation of donated human skin that we process into AlloDerm, Repliform, Cymetra and cryopreserved skin as a temporary wound dressing.

We currently do not have procurement arrangements for other tissues related to products under development, and do not intend to develop such arrangements until the products approach commercialization.

We are accredited by the American Association of Tissue Banks ("AATB"). The AATB is recognized for the development of industry standards and its program of inspection and accreditation. The AATB provides a standards-setting function similar to the FDA`s quality system regulations for medical device companies, and has procedures for accreditation similar to the International Standards Organization ("ISO") standards. Our initial accreditation was granted in 1997 following a detailed audit by the AATB of our operations and procedures. The accreditation, which was renewed in 2000, must be renewed every three years and is for the processing, storage and distribution of tissue used in AlloDerm, Repliform, Cymetra and allograft skin.


10

--------------------------------------------------------------------------------
GOVERNMENT REGULATION

Overview
Government regulation, both domestic and foreign, is a significant factor in the manufacturing and marketing of our current and developing products. In the United States, our human tissue products are subject to regulation by the FDA. The FDA applies the Federal Food, Drug, and Cosmetics Act (the "FDC Act") and the Public Health Service Act (the "PHS Act"). These rules provide the regulations which apply to the testing, manufacturing, labeling, storage, record keeping, approval, advertising and promotion of our products.

The FDA does not apply a single regulatory scheme to human tissues and products derived from human tissue. On a case-by-case basis, the FDA may choose to regulate such products as transplanted human tissue, medical devices or biologics. A fundamental difference in the treatment of products under these various classifications is that the FDA generally permits human tissue for transplantation to be commercially distributed without premarket approval. In contrast, products regulated as medical devices or biologics usually require such approval. The process of obtaining premarket approval for a medical device or biologic is often expensive, lengthy and uncertain.

Once on the market, all of our human tissue products are subject to pervasive and continuing regulation by the FDA. We are subject to inspection at any time by the FDA and state agencies for compliance with regulatory requirements. The FDA may impose a wide range of enforcement sanctions if we fail to comply, including:

- fines,

- injunctions,

- civil penalties,

- recall or seizure of our products,

- total or partial suspension of production,

- refusal of the government to authorize the marketing of new products or to allow us to enter into supply contracts, and

- criminal prosecution.


Tissue Regulation
In 1996, correspondence from the FDA stated that AlloDerm used for the replacement or repair of damaged or inadequate integumental tissue would be regulated as human tissue under an interim regulation governing human tissue for transplantation then in effect. This letter reversed the FDA`s initial position that AlloDerm for these indications should be regulated as a medical device. In 1997, the FDA issued a final regulation that became effective in 1998 regulating "human tissue." The rule defines human tissue as any tissue derived from a human body which is (i) intended for administration to another human for the diagnosis, cure, mitigation, treatment or prevention of any condition or disease and (ii) recovered, processed, stored or distributed by methods not intended to change tissue function or characteristics. The FDA definition excludes, among other things, tissue that currently is regulated as a human drug, biological product or medical device and excludes vascularized human organs.

The final tissue rule requires establishments engaged in the procurement, processing, and distribution of human tissue to conduct donor screening and infectious disease testing and to maintain records available for FDA inspection documenting that the procedures were followed. The rule also provides the FDA with authority to conduct inspections of tissue establishments and to detain, recall, or destroy tissue where the procedures were not followed or appropriate documentation of the procedures is not available.

Relying on the 1996 letter, we have not obtained prior FDA approval for commercial distribution of AlloDerm for use in the treatment of burns, plastic reconstructive surgery procedures (such as atrophic lip reconstruction and scar revision) and periodontal surgical procedures (such as free-gingival grafting and guided tissue regeneration). We believe that the final tissue regulation did not alter the provisions of the interim regulation that was the foundation of the FDA`s decision not to regulate AlloDerm as a device when used for these indications. Therefore, we continue to believe that AlloDerm for these uses is


11

--------------------------------------------------------------------------------
regulated as human tissue. However, because the FDA`s approach to tissue regulation is evolving, we cannot assure you that FDA will adhere to this position. In the future, the FDA could choose to impose device regulation on AlloDerm for these indications.
The FDA also stated in the 1996 letter that their decision applied only to AlloDerm when intended for use in transplantation to repair or replace damaged or inadequate integumental tissue and that the regulatory status of the product when it is promoted for other uses, such as a void filler for soft tissue, for cosmetic augmentation or as a wound healing agent, would be determined on a case-by-case basis.

In 1999, we began marketing two additional tissue products, Repliform and Cymetra. Repliform is the trade name given to AlloDerm when it is labeled for the intended use of repairing damaged or inadequate integumental connective tissue in urological and gynecological surgery. Cymetra is Alloderm that has been micronized at low temperature to create a particulate form of AlloDerm suitable for injection. This form of AlloDerm permits delivery to subcutaneous locations by injection rather than open surgery to repair damaged or inadequate integumental tissue. The micronized particles are biochemically identical to AlloDerm.

In November 2000, the FDA wrote to us and requested detailed information about Repliform and Cymetra, including copies of existing labeling and advertising, a description of product composition and processing, and other information supporting our belief that each of these products is human tissue. In February 2001, we provided a detailed submission responding to the FDA`s request. In June 2001, we received a letter from the FDA indicating that Repliform and Cymetra, as currently marketed, meet the definition of human tissue for transplantation.

In January 2001, the FDA issued a final rule requiring registration of tissue banking establishments and the listing of tissue products. These requirements became effective on April 4, 2001. A proposed regulation pending since September 1999 would require that most tissue donors be screened for relevant communicable diseases. Another proposed regulation issued in January 2001 would require manufacturers of tissue products to follow proposed current good tissue practices. These final and pending regulations demonstrate FDA`s increasingly proactive regulation of human tissue, which may lead to the imposition of significant additional regulatory requirements upon tissue products. Such requirements could cause us to incur significant additional costs.

Procurement of certain human organs and tissue for transplantation is subject to the restrictions of the NOTA, which prohibits the acquisition of certain human organs, including skin and related tissue for valuable consideration, but permits the payment of reasonable expenses associated with the procurement, transportation processing, preservation, quality control and storage of human tissue and skin. We reimburse tissue banks for expenses incurred that are associated with the recovering and transportation of donated human skin that we process into AlloDerm, Repliform, Cymetra and allograft skin as a temporary wound dressing. We include in our pricing structure certain costs associated with processing, preservation, quality control and storage of the tissue, and marketing and medical education expenses in addition to amounts paid to tissue banks to reimburse them for their expenses associated with the removal and transportation.


Medical Device Regulation
A medical device generally may be marketed in the United States only with the FDA`s prior authorization. Devices classified by the FDA as posing less risk are placed in class I or class II. Class II devices (and some class I devices) generally require the manufacturer to seek "510(k) clearance" from the FDA prior to marketing through the filing of a "premarket notification," unless exempted from this requirement by regulation. Such clearance generally is granted based upon a finding that a proposed device is "substantially equivalent" in intended use and safety and effectiveness to a "predicate device," which is a legally marketed class I or II device that already has
510(k) clearance or a "pre-amendment" class III device (in commercial distribution prior to May 28, 1976) for which the FDA has not called for PMA applications (defined below). We believe that it usually takes from 4 to 12 months from the date of submission to obtain 510(k) clearance, but it may take longer. No assurance can be given that any 510(k) submission will ever receive clearance. After a device receives 510(k) clearance, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in the intended use of the device, will require a new 510(k) submission.

A medical device that does not qualify for 510(k) clearance is placed in class III, which is reserved for devices classified by the FDA as posing the greatest risk (e.g., life-sustaining, life-supporting or implantable devices, or devices that are not substantially equivalent to a predicate device). A class III device generally must undergo the premarket approval ("PMA") process, which requires the manufacturer to prove the safety and effectiveness of the device to


12

--------------------------------------------------------------------------------
the FDA`s satisfaction. A PMA application must provide extensive preclinical and clinical trial data and information about the device and its components regarding, manufacturing, labeling and promotion. As part of the PMA review, the FDA will inspect the manufacturer`s facilities for compliance with the Quality System Regulation ("QSR"), which includes elaborate testing, control, documentation and other quality assurance procedures. Upon submission, the FDA determines if the PMA application is sufficient to permit a substantive review, and, if so, the application is accepted for filing. The FDA then commences an in-depth review of the PMA application, which we believe typically takes one to three years, but may take longer.
If the FDA`s evaluation of the PMA application is favorable, the FDA typically issues an "approval letter" requiring the applicant`s agreement to comply with specific conditions (e.g., changes in labeling) or to supply specific additional data (e.g., longer patient follow up) or information (e.g., submission of final labeling) in order to secure final approval of the PMA application. Once the approval letter is satisfied, the FDA will issue a PMA order for the approved indications, which can be more limited than those originally sought by the manufacturer. The PMA order can include post approval conditions that the FDA believes necessary to ensure the safety and effectiveness of the device including, restrictions on labeling, promotion, sale and distribution. Failure to comply with the conditions of approval can result in enforcement action, including withdrawal of the approval. The PMA process can be expensive and lengthy, and no assurance can be given that any PMA application will ever be approved for marketing. Even after approval of a PMA, a new PMA or PMA supplement is required in the event of a modification to the device.

A clinical study in support of a PMA application or 510(k) submission for a "significant risk" device requires an Investigational Device Exemption ("IDE") application approved in advance by the FDA for a limited number of patients. The IDE application must be supported by appropriate data, such as animal and laboratory testing results. The clinical study may begin if the FDA and the appropriate Institutional Review Board ("IRB") at each clinical study site approve the IDE application. If the device presents a "non-significant risk" to the patient, a sponsor may begin the clinical study after obtaining IRB approval without the need for FDA approval. In all cases, the clinical study must be conducted under the auspices of an IRB pursuant to FDA`s regulatory requirements intended for the protection of subjects and to assure the integrity and validity of the data.

If we market medical device products, we will be subject to pervasive and continuing regulation. We will have to comply with these requirements, including the FDA`s labeling regulations, the QSR, the Medical Device Reporting ("MDR") regulations (which require that a manufacturer report to the FDA certain types of adverse events involving its products), and the FDA`s general prohibitions against promoting products for unapproved or "off-label" uses. In addition, class II devices can be subject to additional special controls (e.g., performance standards, post market surveillance, patient registries, and FDA guidelines) that do not apply to class I devices.

In 1997, the FDA told us that NeoDura(TM) (an acellular tissue matrix) for use in dura mater replacement procedures would be classified as a medical device requiring 510(k) clearance and we submitted a 510(k) application. In March 1999, we withdrew this 510(k) submission with the intent to submit a new 510(k) submission after we have addressed several issues raised by the FDA. We have not determined if we will submit a new 510(k) submission for NeoDura.

Based upon relevant precedents, it is not clear whether the FDA will regulate our vascular and orthopedic products now in development as medical devices requiring 510(k) clearance or PMA approval or as human tissue for transplantation.


Biologics Regulation
Biologic products are regulated under the FDC Act and the Section 351(a) of the PHS Act. The PHS Act imposes a special additional licensing requirement, known as a Biologic License. This license imposes very specific requirements upon the facility and the manufacturing and marketing of licensed products to assure their safety, purity, and potency. Some licensed biological products are also subject to batch release by the FDA. That is, the products from a newly manufactured batch cannot be shipped until the FDA has evaluated either a sample or the specific batch records and given permission to ship the batch of product. The PHS Act also grants the FDA authority to impose mandatory product recalls and provides for civil and criminal penalties for violations.

Before conducting the required clinical testing of a biological product, an applicant must submit an IND to the FDA, containing preclinical data demonstrating the safety of the product for human investigational use, information about the manufacturing processes and procedures and the proposed clinical protocol. Clinical trials of biological products typically are


13

--------------------------------------------------------------------------------
conducted in three sequential phases, but may overlap. Phase 1 trials test the product in a small number of healthy subjects, primarily to determine its safety and tolerance at one or more doses. In Phase 2, in addition to safety, the efficacy, optimal dose and side effects of the product are evaluated in a patient population somewhat larger than the Phase 1 trial. Phase 3 involves further safety and efficacy testing on an expanded patient population at geographically dispersed test sites.
All clinical studies must be conducted in accordance with FDA approved protocols and are subject to the approval and monitoring of one or more Institutional Review Boards. In addition, clinical investigators must adhere to good clinical practices. Completion of all three phases of clinical studies may take several years, and the FDA may temporarily or permanently suspend a clinical study at any time.

Upon completion and analysis of clinical trials, the applicant assembles and submits a Biologic License Application containing, among other things, a complete description of the manufacturing process. Before the licenses can be granted, the applicant must undergo a successful establishment inspection. FDA review and approval of a biological product can take several years. We cannot assure you that we will obtain the required approval for ThromboSol platelet storage solution or any other proposed biological products.


Other Regulation
We are subject to various federal, state and local laws, regulations and requirements relating to such matters as safe working conditions, laboratory and manufacturing practices, and the use, handling and disposal of hazardous or potentially hazardous substances used and produced in connection with our research and development work. We cannot assure you that we will not incur significant additional costs to comply with these laws or regulations in the future.


International Regulation
The regulation of our products outside the United States varies by country. Certain countries regulate our human tissue products as a pharmaceutical product, requiring us to make extensive filings and obtain regulatory approvals before selling our product. Certain countries classify our products as human tissue for transplantation but may restrict its import or sale. Other countries have no applicable regulations regarding the import or sale of products similar to our products, creating uncertainty as to what standards we may be required to meet.

AlloDerm and Cymetra are currently distributed in several countries internationally. Additionally, we are pursuing clearance to distribute AlloDerm and Cymetra in certain other countries. The uncertainty of the regulations in each country may delay or impede the marketing of AlloDerm or Cymetra and other products in the future or impede our ability to negotiate distribution arrangements on favorable terms. Certain foreign countries have laws similar to NOTA. These laws may restrict the amount that we can charge for our products and may restrict our ability to export or distribute our products to licensed not-for-profit organizations in those countries. Noncompliance with foreign country requirements may include some or all of the risks associated with noncompliance with FDA regulation as well as other risks.

RESEARCH AND DEVELOPMENT

We have historically funded the development of our human tissue products and blood cell preservation products primarily through external sources, including a corporate alliance and government grants, as well as through the proceeds from equity offerings. Our research and development costs in 1999, 2000 and 2001 for all programs were approximately $3.9 million, $4.5 million and $4.4 million, respectively. See "Management`s Discussion and Analysis of Financial Condition and Results of Operations-Liquidity and Capital Resources."

We have received a substantial portion of our government grant funding from the United States government`s Small Business Innovation Research ("SBIR") program. The SBIR grant program provides funding to evaluate the scientific and technical merit and feasibility of an idea. To date, we have been awarded in excess of $10 million through approved SBIR program awards and Department of Defense contracts. We intend to continue to seek funding through the SBIR programs, as well as to pursue additional government grant and contract programs. Generally, we have the right to patent any technologies developed from government grants and contract funding, subject to the United States government`s right to receive a royalty-free license for federal government use and to require licensing to others in certain circumstances.


14

--------------------------------------------------------------------------------
PATENTS, PROPRIETARY INFORMATION AND TRADEMARKS
Our ability to compete effectively with other companies is dependent materially upon the proprietary nature of our technologies. We rely primarily on patents, trade secrets and confidentiality agreements to protect our technologies. We currently license the exclusive right to nine United States patents and related foreign patents and the non-exclusive right to 14 United States patents. In addition, we have been issued five United States utility patents, one United States design patent and have seven pending United States patent applications.

Our technology is protected by three primary families of patents and patent applications. One United States patent covers methods of producing our tissue-based products. Nine additional United States patents supplement this patent and cover methods of freeze-drying without the damaging effects of ice crystal formation. Two United States patents and two pending patent applications cover methods of extending the shelf-life of platelets, red blood cells and other blood cells.

We also have applied for patent protection in several foreign countries. Because of the differences in patent laws and laws concerning proprietary rights, the extent of protection provided by United States patents or proprietary rights owned by or licensed to us may differ from that of their foreign counterparts.

In general, the patent position of biotechnology and medical product firms is highly uncertain and involves complex legal, scientific and factual questions. There is risk that other patents may not be granted with respect to the patent applications filed by us. Furthermore, there is risk that one or more patents issued or licensed to us will not provide commercial benefit to us or will be infringed, invalidated or circumvented by others. The United States Patent and Trademark Office currently has a significant backlog of patent applications, and the approval or rejection of patents may take several years.

Prior to actual issuance, the contents of United States patent applications are generally not made public. Once issued, a patent would constitute prior art from its filing date, which might predate the date of a patent application on which we rely. Conceivably, the issuance of such a prior art patent, or the discovery of "prior art" of which we are currently unaware, could invalidate a patent of ours or our licensor or discourage commercialization of a product claimed within such patent.

No assurances may be given that our products or planned products may not be the subject of additional infringement actions by third parties. Any successful patent infringement claim relating to any products or planned products could have a material adverse effect on our financial condition and results of operations. Further, there can be no assurance that any patents or proprietary rights owned by or licensed to us will not be challenged, invalidated, circumvented, or rendered unenforceable based on, among other things, subsequently discovered prior art, lack of entitlement to the priority of an earlier, related application or failure to comply with the written description, best mode, enablement or other applicable requirements.

We generally conduct a cursory review of issued patents prior to engaging in research or development activities. If others already have issued patents covering new products that we develop, we may be required to obtain a license from others to commercialize such future products. There can be no assurance that any such license that may be required could be obtained on favorable terms or at all.

We may decide for business reasons to retain certain knowledge that we consider proprietary as confidential and elect to protect such information as a trade secret, as business confidential information, or

[Neoe]

So , und hier noch was , was den Kurs antreiben könnte:

LifeCell CEO Paul Thomas to Present at NYSSA Health Care Conference On March 26th

BRANCHBURG, N.J., March 22 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC), a leader in developing and commercializing biological solutions to repair or replace the body`s damaged tissue, announced today that CEO and President, Paul Thomas will present at the 6th Annual New York Society of Security Analysts` Healthcare Conference on March 26th at 11:20 AM at The City Athletic Club.

Mr. Thomas will provide an overview of the Company and outline key milestones for 2002.

LifeCell is a leader in developing and marketing biologically based solutions for the repair and replacement of damaged or inadequate human tissue in numerous different clinical applications. The Company`s proprietary patented tissue matrix technology removes all cells from allograft human tissue and preserves the tissue without damaging the essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently markets four human tissue based products: AlloDerm(R) for plastic reconstructive and burn procedures through LifeCell`s direct sales force and for periodontal procedures through BioHorizons, Inc.; Cymetra(TM), a version of AlloDerm in particulate form for non-surgical correction of soft tissue defects, through LifeCell`s direct sales force and a co-promotion agreement with OMP, Inc.; Repliform(TM), a version of AlloDerm for urology and gynecology procedures, through a marketing and distribution agreement with Boston Scientific Corporation; and cryopreserved allograft skin for use as a temporary wound dressing in the treatment of burns. The Company`s development programs include the potential application of its tissue matrix technology to vascular, nerve and orthopedic tissues; investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red blood cells for transfusion.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, such as our expectations for product development. Forward-looking statements represent management`s judgment regarding future events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements due to a number of factors. These factors include the risks detailed in the Company`s Annual Report on Form 10-K for the year ended December 31, 2000 and other reports filed with the Securities and Exchange Commission.

[drpaulo2001]

Hallo ,bin überzeugt das die 4 euro halten .Habe mit dem Beitrag nur verstanden das eine Konferenz ist .Bitte das andere in Deutsch.
drpaulo2001

[Neoe]

drpaulo@:
Lifecell wird sich auf einer Analystenkonferenz präsentieren. Es geht um Healthcare-Unternehmen und Lifecell wird den Analysten einen Überblick über die Firma verschaffen und etwas zu den Meilensteinen , die man 2002 erreichen möchte , sagen.
Vielleicht springen die Analysten ja endlich mal auf den Zug auf.

[drpaulo2001]

Hallo neoe,bin gerade von der Arbeit zurück.Gibt es schon Meinungen zu Lifecell ,bin in Lifecell voll investiert.
drpaulo2001

[Neoe]

LIFC ist jetzt an der Reihe. Wenn alles nach Plan läuft in 5 Minuten.

[BOERSENMOSES]

Wie die Wertpapierexperten von "Global Biotech Investing" berichten, können die Aktien von Lifecell eine gute Kursentwicklung vorweisen. Schon seit Wochen laufe der Kurs unter hohen Umsätzen nach oben. Inzwischen habe sich die Notierung seit Anfang des Jahres nahezu verdoppelt. Die jüngst präsentierten Zahlen würden den Anstieg bekräftigen. Das Unternehmen habe im letzten Jahr einen Umsatz von 27,8 Millionen US-Dollar erzielen können. Der Verlust habe sich auf 0,14 US-Dollar belaufen, während die Markterwartungen bei 0,16 US-Dollar je Anteilsschein gelegen hätten. Im vierten Quartal habe die Gesellschaft sogar die Gewinnschwelle erreichen können. Das intensive Kostenmanagement werde sich außerdem zusätzlich positiv auf das Ergebnis der Firma auswirken. Daher halten die Analysten von "Global Biotech Investing" die Aktien von Lifecell für ein interessantes Investment.
Lifecell sollte nach nun schon eine zeitlanger Konsoldierung
nun bald mit neuen Meldungen weitere Spruenge nach oben machen.


GRUSS BOERSENMOSES

[Neoe]

Boersenmoses@:
Ein Kurssprung ist tatsächlich drin. Im Moment ist eher Langeweile eingekehrt. Und positive News haben nur den erwünschten Effekt , wenn sie keiner erwartet. Das Feld ist bestellt...

[drpaulo2001]

Hallo neoe,bin heute in Frankfurt fett eingestiegen .Habe mir 25000 Stück nachgekauft ,habe jetzt 45000 stück .Denkst du es lohnt sich
. drpaulo2001

[Bombenleger]

@ drpaulo2001,

willst wohl ein bischen angeben du Kasper.

Geht gar nicht wurden nur 11130 Stück gehandelt.

Erzähl also nicht so ein Blödsinn.

[drpaulo2001]

Hi bombenleger,erstens bin ich kein Kasper und zweitens kann ich nichts dafür wenn der Auftrag von 25000 stück nicht kanns ausgeführt worden ist ,dann wird der rest in den nächsten tagen gekauft .Nicht war du kleine nase.drpaulo2001

[BOERSENMOSES]

HE SEID NETT ZUEINANDER.WIR SITZEN DOCH ALLE IN EINEM BOOT
UND WOLLEN MIT LIFECELL KRAEFTIG VERDIENEN!
WENN JEMAND WAS NEUES WAHRES HOERT EINFACH REINSETZEN.


GRUSS UND PEACE

BOERSENMOSES

[Neoe]

drpaulo@:
Ja , ja , daß tut uns natürlich leid , daß du noch nicht alle bekommen hast. Vielleicht solltest du aber lieber in die Schule gehen und Englisch lernen , anstatt hier die halbe Lifecell Corp. aufzukaufen. Zumindest könntest du dann die ad-hocs deines Investments auch verstehen , wenn mal gerade keiner Lust hat sie zu übersetzten......
Bis du die restlichen Teile eingesackt hast , wird es wohl noch etwas dauern. Du scheinst im Schnitt 50er-Pakete abzusahnen. Taktisch clever , muß ja nicht gleich jeder merken , daß hier ein großer Fisch einsteigt!!!

[BOERSENMOSES]

27.02.2002 - LifeCell meldet Rekordumsatz für 2001

Die LifeCell Corporation (Nasdaq: LIFC), führend in Entwicklung und Vermarktung von Gewebeersatz, gab die Ergebnisse für das am 31. Dezember 2001 endende vierte Quartal sowie für das Geschäftsjahr 2001 bekannt. Im Vergleich zum vierten Quartal 2000 sind die Umsätze um 19% von $5,6 Mio. auf $6,7 Mio. gestiegen. Verantwortlich hierfür waren vor allem die Umsätze mit den Produkten AlloDerm und Repliform. Der Nettogewinn steigerte sich von einem Vorjahresverlust von $2,2 Mio. auf $102.000. im Geschäftsjahr 2001 stieg der Umsatz sogar um 25% von $21,3 Mio. in 2000 auf aktuell $26,6 Mio. Der Nettoverlust verringerte sich von $7,1 Mio. auf $2,1 Mio. und ist neben den gesteigerten Produktumsätzen auch auf eine Kostenreduzierung im Bereich Verwaltung zurückzuführen.

NOCH EINE AUFFRISCHUNG ZU LIFECELL!


GRUSS BOERSENMOSES

[Bombenleger]

April 02, 2002

LIFECELL CORP (LIFC)

form 8-K

Item 5. Other Events.

On April 2, 2002, LifeCell Corporation announced the resignation of a member of the Board of Directors and the appointment of a new member to the Board of
Directors and issued the press release attached to this Current Report on Form 8-K as Exhibit 99.1.

[drpaulo2001]

Hallo neoe ,bist du auch so eine kleine nase oder warum schreibst du so ein shit .Bad guy .......drpaulo2001

[Neoe]

drpaulo@:
Ich habe wirklich kein Interesse daran , die Wenigen , die das Lifecell-Potential erkannt haben ,zu vertreiben.
Aber ich halte nichts davon , mit dir ein Gespräch über irgendwelche utopischen Aktienkäufe zu führen. Nach dem Motto: Wer hat den Größten?
Einen Pluspunkt gibt es jedoch dafür , daß du erkannt hast , daß hier in die erfolgreiche Zukunft investiert wird.

[drpaulo2001]

Hi neoe,dem ist nichts hinzuzufügen.drpaulo2001

[Neoe]

LifeCell Appoints Jonathan Silverstein to the Board of Directors

BRANCHBURG, N.J., April 2 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC), a leader in developing and commercializing biological solutions to repair or replace the body`s damaged tissue, announced today that Jonathan Silverstein will join LifeCell`s Board of Directors. Mr. Silverstein will replace Dr. Peter Costantino who has resigned from the Company`s Board of Directors for personal reasons.

Mr. Silverstein is a Director at OrbiMed Advisors LLC ("OrbiMed"), one of the world`s largest and most successful healthcare fund managers. OrbiMed manages roughly $4 billion dollars in global healthcare assets through 7 different funds. Mr. Silverstein joined OrbiMed in 1999 to focus on private equity and structured investments in small-capitalization public companies. From 1996 to 1999, Mr. Silverstein was the Director of Life Sciences in the investment banking department at Sumitomo Bank, Limited. During his tenure, Mr. Silverstein directed strategic alliances, mergers and acquisitions for the Bank`s clients in the biotechnology and pharmaceutical sectors. Prior to 1996, Mr. Silverstein was an associate at Hambro Resources Development. Mr. Silverstein has a B.A. in Economics from Denison University and a J.D. and M.B.A. from the University of San Diego. Currently, Mr. Silverstein is a Director of Given Imaging, Ltd. (Nasdaq: GIVN) and Predix Pharmaceuticals, Inc.

OrbiMed led a privately negotiated investment in LifeCell in July 2001 and the firm currently holds approximately 12 percent of the Company. Mr. Silverstein stated, "When we looked at the competitive landscape in the biosurgery sector last summer, it was clear that LifeCell`s management was creating a leading company with the right mix of products and partners. Another distinguishing feature was LifeCell`s ability to reach profitability, which happened in the fourth quarter of 2001. I look forward to working with LifeCell`s management and board to find the right mix of investment, product development and acquisitions to accelerate the Company`s growth." As per an OrbiMed policy, Mr. Silverstein will only serve one term on the LifeCell board of directors.

Paul Thomas, President and CEO of LifeCell added, "Jonathan`s experience in corporate finance, strategic alliances, and mergers and acquisitions will prove invaluable as we bring LifeCell to the next phase of corporate development. His financial acumen will complement the rest of the board`s strengths and help LifeCell to formulate future growth strategies. We are delighted that someone of his caliber will join us and believe it underscores LifeCell`s attractiveness as a company."

"We would also like to thank Dr. Costantino for his invaluable contributions as a board member since 1999." Mr. Thomas added.


..........
Zwar nicht ganz neu , aber sehr interessant. Könnte einiges daraus resultieren , muß aber natürlich nicht.
Jedenfalls gut zu wissen , daß der Haupanteilseigner sich engagiert , die Beziehungen von OrbiMed sind erstklassig.

[skaya]

@all
In conjunction with LifeCell Corporation``s First Quarter Earnings Release, Paul G. Thomas, Chairman, President
and CEO of LifeCell Corporation will be hosting a conference call on Tuesday, April 23, 2002 at 11:00 AM ET. A
listen-only, live webcast of the conference call will be available at the following link:
http://www.videonewswire.com/event.asp?id=4350." target="_blank" rel="nofollow ugc noopener">http://www.videonewswire.com/event.asp?id=4350. (Minimum requirements to listen to the webcast: The
RealPlayer software, downloadable free from http://www.real.com/products/player/index.html, and at least a
14.4Kbps connection to the Internet.)

What: First Quarter 2002 Earnings Release When: Tuesday, April 23, 2002 11:00 AM ET Conference Call
Information Call-in #: 1-800-867-4593 Access Code: LifeCell Replay #: 1-800-938-1584 -- Available
approximately 1 hour after event ends. From April 23, 2002 through April 30, 2002 Contact: Steven Sobieski, VP,
CFO, 908-947-1100

LifeCell is a leader in developing and marketing biologically based solutions for the repair and replacement of
damaged or inadequate tissue in numerous different clinical applications. The Company``s proprietary patented
tissue matrix technology removes all cells from allograft tissue and preserves the tissue without damaging the
essential biochemical and structural components necessary for normal tissue regeneration. LifeCell currently
markets three proprietary human tissue based products: AlloDerm(R) for plastic reconstructive and burn
procedures through LifeCell``s direct sales force and for periodontal procedures through BioHorizons, Inc.;
Cymetra(TM), a version of AlloDerm in particulate form for the correction of soft tissue defects, through LifeCell``s
direct sales force and a co-promotion agreement with OMP, Inc.; and Repliform(TM), a version of AlloDerm for
urology and gynecology procedures, through a marketing and distribution agreement with Boston Scientific
Corporation. The Company``s development programs include the application of its tissue matrix technology to
vascular, nerve and orthopedic tissue repair; investigation of human tissues as carriers for therapeutics;
Thrombosol(TM), a formulation for extended storage of platelets and technologies to enhance the storage of red
blood cells for transfusion.

If you are unable to participate during the live webcast, the call will be archived on the Web site "LifeCell
Corporation``s Financial Section."

http://www.videonewswire.com/event.asp?id=4350 LifeCell Corporation

© PR Newswire

[Neoe]

Negative Überraschungen sind am Dienstag nicht zu erwarten. Lifecell enttäuscht ja bekanntlich nicht. Sie gehören wahrscheinlich eher zu denen , die höhere Einnahmen als erwartet vermelden können.

[skaya]

@all
hier die Zahlen.
Viele Grüße
Skaya
LifeCell Corporation , a leader in the development and commercialization of biologically based solutions to repair or
replace the body``s damaged tissue, today reported financial results for the first quarter ended March 31, 2002.

First Quarter Highlights: -- Record product revenues of $7.3 million and net income of $436,000, which includes a
tax benefit of $248,000; -- Awarded $824,000 grant from the Office of Navel Research to continue the Company``s
cell preservation program, including initiatives to develop biologic products that would enable practical blood
storage and mass availability; and -- Announced partnership with LifeNet to increase availability of allograft skin
tissue for burn victims. First Quarter Financial Results:

The Company reported total revenue of $7.7 million for the first quarter of 2002, up 13 percent from $6.8 million
for the same period in 2001. Product revenues of $7.3 million were 14 percent above the $6.4 million reported for
the first quarter of 2001. The increase was largely due to a 26 percent increase in AlloDerm(R) revenues which
grew to $3.8 million in the quarter compared to $3.0 million in the first quarter of 2001. Repliform revenues also
increased in the quarter to $2.3 million from $2.2 million in the same quarter in 2001. Cymetra revenues were $1.0
million in the first quarter of 2002 and 2001. Research grant revenues were $349,000 for the first quarter of 2002,
essentially the same as reported in the prior year.

Net income for the first quarter of 2002 rose to $436,000, or $.02 per share, compared to a net loss of $1.3 million,
or $.09 per share, in the first quarter of 2001. Net income in the first quarter of 2002 includes a $248,000 tax
benefit related to the sale of state tax net operating losses. Excluding the tax benefit, net income for the first
quarter of 2002 was $188,000.

The improvement in operating results for the first quarter of 2002 was principally due to the increase in product
revenues, a reduction in costs of products sold resulting from operating efficiencies, lower selling and marketing
expenses and lower interest expense. During the quarter, the Company maintained its steady commitment to
research and product development activities to fuel future growth. Research and development spending
approximated $1.1 million in the first quarter of each year.

The Company ended the quarter with cash and short-term investments of approximately $5.2 million compared to
$4.9 million at December 31, 2001.

"Product revenues and net income were in line with our expectations for the quarter and we expect to meet our
revenue growth guidelines of 20% and net income target of approximately one million dollars for the full year
2002," said Paul Thomas, President and CEO of LifeCell. "We remain focused on delivering improved operating
results while continuing to invest in ongoing product development initiatives and searching for complementary
product opportunities for our direct sales organization."

Conference Call:

As previously reported, a conference call will be conducted by LifeCell management today, April 23, 2002 at 11:00
a.m. Eastern time to discuss these operating results and related matters. You may listen to the conference call by
calling [phone] and indicating access code: LifeCell. The conference call will be recorded and an automated
playback of the conference call will be available through April 30, 2002 by dialing [phone] and indicating
access code LifeCell.

A listen-only, live webcast of the conference call will be available at
http://www.videonewswire.com/event.asp?id=4350." target="_blank" rel="nofollow ugc noopener">http://www.videonewswire.com/event.asp?id=4350. If you are unable to listen during the live webcast, the call will
be archived on LifeCell``s web site http://www.lifecell.com/ through April 30, 2002.

About LifeCell

LifeCell is a leader in developing and marketing biologically based solutions for the repair and replacement of
damaged or inadequate tissue in numerous different clinical applications. The Company``s proprietary tissue matrix
technology removes cells from allograft tissue and preserves the tissue without damaging the essential biochemical
and structural components necessary for normal tissue regeneration. LifeCell currently markets three proprietary
human tissue based products: AlloDerm(R) for plastic reconstructive and burn procedures through LifeCell``s direct
sales force and for periodontal procedures through BioHorizons, Inc.; Cymetra(R), a version of AlloDerm in
particulate form for the correction of soft tissue defects, through LifeCell``s direct sales force and a co-promotion
agreement with OMP, Inc.; and Repliform(TM), a version of AlloDerm for urology and gynecology procedures,
through a marketing and distribution agreement with Boston Scientific Corporation. The Company``s development
programs include the application of its tissue matrix technology to vascular, nerve and orthopedic tissue repair;
investigation of human tissues as carriers for therapeutics; Thrombosol(TM), a formulation for extended storage of
platelets and technologies to enhance the storage of red blood cells for transfusion. Visit our website at
http://www.lifecell.com/.

This release contains forward-looking statements made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, such as our guidance for 2002 revenues and net income expectations,
ability to acquire and market additional products, product development efforts and entry into target markets.
Forward-looking statements represent management``s judgment regarding future events. Although management
believes that the expectations reflected in such statements are reasonable, they give no assurance that such
expectations will prove to be correct and you should be aware that actual results could differ materially from those
contained in the forward-looking statements due to a number of factors. These factors include the risks detailed in
the Company``s Annual Report on Form 10-K for the year ended December 31, 2001 and other reports filed with
the Securities and Exchange Commission.

LIFECELL CORPORATION Financial Highlights (Unaudited) Statement of Operations Data: Three months ended
March 31, 2002 2001 Revenues: Product revenues $7,310,000 $6,424,000 Research grant revenues 349,000
347,000 Total revenues 7,659,000 6,771,000 Costs and expenses: Cost of products sold 2,396,000 2,495,000
Research and development 1,080,000 1,125,000 General and administrative 1,086,000 1,093,000 Selling and
marketing 2,858,000 3,197,000 Total costs and expenses 7,420,000 7,910,000 Income (loss) from operations
239,000 (1,139,000) Interest and other income (expense), net (51,000) (177,000) Income (loss) before income
taxes 188,000 (1,316,000) Income tax benefit 248,000 -- Net income (loss) 436,000 (1,316,000) Preferred stock
dividends -- (143,000) Net income (loss) applicable to common stockholders $436,000 $(1,459,000) Net income
(loss) per common share: Basic $0.02 $(0.09) Diluted $0.02 $(0.09) Shares used in computing net income (loss)
per common share: Basic 20,777,407 16,709,368 Diluted 25,076,643 16,709,368 Balance Sheet Data: March 31,
December 31, 2002 2001 Cash and cash equivalents and short-term investments $5,155,000 $4,900,000 Working
capital 9,439,000 8,851,000 Total assets 23,330,000 23,131,000 Total stockholder``s equity 15,269,000 14,833,000

http://www.videonewswire.com/event.asp?id=4350 LifeCell Corporation

© PR Newswire

[Neoe]

Sie wachsen weiter ohne in der Vergangenheit auch nur einen signifikanten Umsatzrückgang zu beklagen.
Lifecell rules , glaubt es mir.

[patricktietz]

Warum haben Lifecell Aktien über 7 Prozent in den USA verloren?

Gibt es dazu News oder liegt es an der Charttechnik?

mfg Pat

[drpaulo2001]

Ich greife bei 2,20euro wieder zu ,oder neoe.drpaulo

[Neoe]

Keine Ahnung warum Lifecell fällt. Alles läuft nach Plan. Da ich nicht mehr trade , halte ich meine Aktien , bei auf und ab. Selbes Szenario as every time. Die Dinger fallen meiner Meinung nach höchstens bis 2,5$ und steigen danach genau so schnell wieder über 3$.

[drpaulo2001]

Hallo neoe, lifecell ist im + .Was denkst du wenn der biocrash vorbei ist?Wo wird dann lifecell stehen ,und hast du ein kz bis nächsten Sommer.drpaulo2001

[Neoe]

Leider wieder etwas Langeweile im Hause Lifecell , dafür lassen sie aber negative Nachrichten erst gar nicht entstehen und präsentieren uns in etwas größeren Abständen die positiven , die mittlerweile schon jeder erwartet.
Aber eines Tages kommen die Neuentwicklungen und dann werden einige heulen , weil sie die Chance verpasst haben
(Kubrick , würd dir wünschen , daß du nicht zu ihnen gehörst , hast dich immerhin schon lange mit dem Ding befasst und hättest es nicht verdient, bis denne).

[Kubrick2001]

Hallo Neoe,

ich beobachte Lifecell weiterhin sehr aufmerksam, die Fundamentale Entwicklung ist in Ordnung. Der Cash-Flow mit den bestehenden Produkten positiv. Werde demnächst mein Lifecell Paket zurückkaufen und dann auch wieder zu Lifecell schreiben.

Gruß Kubrick

[skaya]

Ich denke, ich werde noch ein paar Stück nachkaufen. Der Wert
hält sich ja für diese -höflich ausgedrückt- bescheidene Börsensituation
meiner Ansicht nach ausgesprochen gut.
@Neoe
Du hast Recht damit, dass die Firma negative Nachrichten gar nicht erst entstehen
lässt. Was aber wenn...??? Das jeder die positiven erwartet, dass ist gerade die Gefahr,
die in diesem Wert besteht.
Aber wer nicht wagt, der nicht gewinnt, oder???
Grüße
Skaya

[drpaulo2001]

Hallo neoe,habe mir heute 1200 lifecell zugelegt .Was denkst du wo sie stehen werden wenn der bioindex wieder die 800 punkte sieht.drpaulo2001

[lifecell2002]

Hallo ,bin hier neu .Habe von meinem freund die lifecell empfohlen bekommen.Er meinte der bioindex hätte eine crash von fast 65%seit dem Höchstand erlebt und meint man könnte jetzt im biosektor einsteigen.Ermeinte lifecell undpdli wären seine Favoriten ,also habe ich mein Geld vom Sparbuch genommen und mir lifcell un pdli gekauft.Ich hoffe es war kein fehler den es sind immerhin 60000 euro.Sagt mir eure Meinung.

[Newman8]

Bin zwar auch in Lifecell investiert,aber was Du da schreibst glaubst Du doch selber nicht.
(Wer bis jetzt 60000 Euro auf dem Sparbuch hatte,kauft bestimmt nicht solche Werte.

[lifecell2002]

Dann glaube es halt nicht.Übrigens mein Freund ist bei der bank im investbereich .Er meinte das lifecell in letzter Zeit keine große bewegung gemacht hat ,aber der index und die big player sehr große crash erlebt haben .Er sagte ich soll sie mir kaufen und nicht jeden Tag hinschauen.Was meint ihr denn kann man kaufen wenn nicht diese Werte .P.S ich denke mein Freund hat ein wenig Ahnung denn er ist schon20 Jahre in der Branche.Grußlifecell2002

[Neoe]

BRANCHBURG, N.J., May 9 /PRNewswire-FirstCall/ -- LifeCell Corporation (Nasdaq: LIFC), a leader in developing and commercializing biologically based solutions to repair or replace the body`s damaged tissue, announced today that it entered into an agreement with LifeNet and Arthrex Tissue Systems, Inc. (ATSI) to develop and market acellular allografts for sports medicine applications. LifeNet is the largest organ procurement based tissue bank in the United States and ATSI is a leading provider of medical products for sports medicine. The three parties formed the alliance to combine their expertise to produce acellular allografts for sports medicine that will be used in procedures such as anterior cruciate ligament (ACL) repair.

Under the terms of the agreement, LifeCell will use its proprietary tissue matrix technology to process allograft tissue recovered by LifeNet and its Recovery and Alliance Partners into acellular allografts that will be marketed by ATSI to their extensive network of orthopedic surgeons.

"Based on the success of our three marketed products, we are excited about the potential use of our acellular allografts in sports medicine applications. We anticipate these acellular allografts will demonstrate benefits to patients and minimize the need to harvest the patient`s own tissue for the replacement of damaged tendons and ligaments," said Paul Thomas, President and CEO of LifeCell.

Industry reports estimate that over 100,000 ACL injuries occur every year in the U.S. With the aging of the population and the active lifestyle of the "baby-boomer" generation, ACL and other soft tissue injuries are growing at a rate of at least 10 percent annually.

"We are partnering with LifeCell and ATSI to provide patients with what we believe will be a superior product that should help to eliminate certain complications associated with the use of an autograft and traditional frozen, freeze dried and cryopreserved allografts," said Bill Anderson, LifeNet`s President and Chief Executive Officer. "We are confident this collaboration will help us with our goal of ensuring that donated human tissue is available to help as many patients as possible."

Financial terms of the agreement were not disclosed.

[Newman8]

@ lifecell2002
Wie ich schon schrieb,bin selber in lifecell investiert,und glaube auch an steigende Kurse in der Zukunft.
Ich frage mich nur,warum Du 60.000 € auf dem Sparbuch hast (hattest) wenn Du so einen Freund hast.
Ps.Im übriegen wurde vor zwei Jahren auch gesagt,"Einfach kaufe,und nach ein paar Jahren erst wieder auf den Kurs schauen."
Ich möchte nicht der sein,der diesem Rat gefolgt ist.
Gerade solche Werte sollte man im Auge haben,man weiss nie welche nachrichten vom Unternehmen kommen.
Gruß Newman8

[lifecell2002]

Hallo Newmann8, habe den Fehler gesehen .Ich habe mich um eine 0 vertippt.lifecell2002

[Newman8]

@ lifecell2002
Naja,dann kann ich das auch glauben,6.000€ hört sich schon anders an!
PS Hier im Board wird manchmal so übertrieben,deswegen wollte ich das mal los werden.
Also viel Erfolg. :-)

[tui66]

@neoe:
bahnt sich da eine trendwende an?
wie siehst Du die Aktie heute?
tui66